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A B S T R A C T
Background
Surgical site infections (SSI) can delay wound healing, impair cosmetic outcome and increase healthcare costs. Topical antibiotics are
sometimes used to reduce microbial contaminant exposure following surgical procedures, with the aim of reducing SSIs.
Objectives
The primary objective of this review was to determine whether the application of topical antibiotics to surgical wounds that are healing
by primary intention reduces the incidence of SSI and whether it increases the incidence of adverse outcomes (allergic contact dermatitis,
infections with patterns of antibiotic resistance and anaphylaxis).
Search methods
InMay 2015 we searched: the CochraneWounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL;
the Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid Embase and EBSCO
CINAHL. We also searched clinical trial registries for ongoing studies, and bibliographies of relevant publications to identify further
eligible trials. There was no restriction of language, date of study or setting. The search was repeated in May 2016 to ensure currency
of included studies.
Selection criteria
All randomized controlled trials (RCTs) and quasi-randomised trials that assessed the effects of topical antibiotics (any formulation,
including impregnated dressings) in people with surgical wounds healing by primary intention were eligible for inclusion.
Data collection and analysis
Two review authors independently selected studies and independently extracted data. Two authors then assessed the studies for risk
of bias. Risk ratios were calculated for dichotomous variables, and when a sufficient number of comparable trials were available, trials
were pooled in a meta-analysis.
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Main results
A total of 10 RCTs and four quasi-randomised trials with 6466 participants met the inclusion criteria. Six studies involved minor
procedures conducted in an outpatient or emergency department setting; eight studies involved major surgery conducted in theatre.
Nine different topical antibiotics were included. We included two three-arm trials, two four-arm trials and 10 two-arm trials. The
control groups comprised; an alternative topical antibiotic (two studies), topical antiseptic (six studies) and no topical antibiotic (10
studies), which comprised inert ointment (five studies) no treatment (four studies) and one study with one arm of each.
The risk of bias of the 14 studies varied. Seven studies were at high risk of bias, five at unclear risk of bias and two at low risk of bias.
Most risk of bias concerned risk of selection bias.
Twelve of the studies (6259 participants) reported infection rates, although we could not extract the data for this outcome from one
study. Four studies (3334 participants) measured allergic contact dermatitis as an outcome. Four studies measured positive wound
swabs for patterns of antimicrobial resistance, for which there were no outcomes reported. No episodes of anaphylaxis were reported.
Topical antibiotic versus no topical antibiotic
We pooled the results of eight trials (5427 participants) for the outcome of SSI. Topical antibiotics probably reduce the risk of SSI
in people with surgical wounds healing by primary intention compared with no topical antibiotic (RR 0.61, 95% CI 0.42 to 0.87;
moderate-quality evidence downgraded once for risk of bias). This equates to 20 fewer SSIs per 1000 patients treated with topical
antibiotics (95% CI 7 to 29) and a number needed to treat for one additional beneficial outcome (NNTB) (i.e. prevention of one SSI)
of 50.
We pooled the results of three trials (3012 participants) for the outcome of allergic contact dermatitis, however this comparison was
underpowered, and it is unclear whether topical antibiotics affect the risk of allergic contact dermatitis (RR 3.94, 95% CI 0.46 to
34.00; very low-quality evidence, downgraded twice for risk of bias, once for imprecision).
Topical antibiotic versus antiseptic
We pooled the results of five trials (1299 participants) for the outcome of SSI. Topical antibiotics probably reduce the risk of SSI in
people with surgical wounds healing by primary intention compared with using topical antiseptics (RR 0.49, 95% CI 0.30 to 0.80;
moderate-quality evidence downgraded once for risk of bias). This equates to 43 fewer SSIs per 1000 patients treated with topical
antibiotics instead of antiseptics (95% CI 17 to 59) and an NNTB of 24.
We pooled the results of two trials (541 participants) for the outcome of allergic contact dermatitis; there was no clear difference in the
risk of dermatitis between topical antibiotics and antiseptics, however this comparison was underpowered and a difference cannot be
ruled out (RR 0.97, 95% CI 0.52 to 1.82; very low-quality evidence, downgraded twice for risk of bias and once for imprecision).
Topical antibiotic versus topical antibiotic
One study (99 participants) compared mupirocin ointment with a combination ointment of neomycin/polymyxin B/bacitracin zinc
for the outcome of SSI. There was no clear difference in the risk of SSI, however this comparison was underpowered (very low-quality
evidence downgraded twice for risk of bias, once for imprecision).
A four-arm trial involved two antibiotic arms (neomycin sulfate/bacitracin zinc/polymyxin B sulphate combination ointment versus
bacitracin zinc, 219 participants). There was no clear difference in risk of SSI between the combination ointment and the bacitracin
zinc ointment. The quality of evidence for this outcome was low, downgraded once for risk of bias, and once for imprecision.
Authors’ conclusions
Topical antibiotics applied to surgical wounds healing by primary intention probably reduce the risk of SSI relative to no antibiotic, and
relative to topical antiseptics (moderate quality evidence). We are unable to draw conclusions regarding the effects of topical antibiotics
on adverse outcomes such as allergic contact dermatitis due to lack of statistical power (small sample sizes). We are also unable to draw
conclusions regarding the impact of increasing topical antibiotic use on antibiotic resistance. The relative effects of different topical
antibiotics are unclear.
P L A I N L A N G U A G E S U M M A R Y
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Topical antibiotics (applied to the skin) for preventing surgical site infection in wounds that are stitched or held together
another way
Background
The presence of micro-organisms, such as bacteria, at wound sites following surgery can result in surgical site infections for patients.
Surgical site infections can result in increased healthcare costs, delays in wound healing and pain. Antibiotics are medicines that kill
bacteria or prevent them from developing. Antibiotics can be taken by mouth (orally), directly into veins (intravenously), or applied
directly to the skin (topically). Topical antibiotics are often applied to wounds after surgery because it is thought that they prevent
surgical site infection. There are thought to be benefits in using antibiotics topically rather than orally or intravenously. As topical
antibiotics act only on the area of the body where they are applied, there is less likelihood of unwanted effects that affect the whole
body, such as nausea and diarrhoea. Topical antibiotics are also thought to reduce the chances of bacterial resistance (bacteria changing
to become resistant to medication). However topical antibiotics can also have unwanted effects, the most common being an allergic
reaction on the skin (contact dermatitis), which can cause redness, itching and pain at the site where the topical antibiotic was applied.
Review question
We reviewed the evidence about how effective topical antibiotics are in preventing surgical site infection if applied directly to wounds
after surgery. We focused on the effect of topical antibiotics on the type of surgical wound where the edges are held closely together
so that the wound heals more easily (known as healing by primary intention). The edges of these wounds can be held together with
stitches, staples, clips or glue.
What we found
In May 2016 we searched for as many relevant studies as we could find that investigated the use of topical antibiotics on surgical
wounds healing by primary intention. We managed to identify 14 studies which compared topical antibiotics with no treatment, or
with antiseptics (i.e. other treatments applied to the skin to prevent bacterial infection), and with other topical antibiotics. Eight of
these trials involved general surgery and six involved dermatological surgery (surgery involving only the skin). Many of the studies
were small, and of low quality or at risk of bias. After examining them all, the authors concluded that the risk of having a surgical site
infection was probably reduced by the use of topical antibiotics applied to wounds after surgery, whether the antibiotics were compared
with an antiseptic, or to no treatment. As infection is a relatively rare event after surgery, the actual reduction in the rate of infection
was 4.3% on average when the use of topical antibiotic was compared with antiseptic, and 2% when use of the topical antibiotic was
compared with no treatment. It would require 24 patients on average to be treated with topical antibiotics instead of antiseptic, and 50
patients to be treated with topical antibiotic compared to no treatment in order to prevent one wound infection. Four studies reported
on allergic contact dermatitis, but there was insufficient evidence to determine whether allergic contact dermatitis occurred any more
frequently with topical antibiotics than with antiseptics or no treatment, and this should also be considered before deciding to use
them.
This plain language summary is up to date as of May 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Topical ant ibiot ics compared with no topical ant ibiot ic for surgical wounds healing by primary intent ion
Patient or population: people presenting for surgery where healing of surgical wound(s) was planned to be by primary intention
Setting: primary or secondary care
Intervention: topical antibiotic
Comparison: no topical antibiotic
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no treatment
control
Risk with topical an-
tibiotic
Surgical site infect ion Study populat ion RR 0.61
(0.42 to 0.87)
5427
(7 RCTs and 1 Q-RCT)
⊕⊕⊕©
MODERATE 1
Downgraded for risk of
bias (-1)
51 per 1000 31 per 1000
(21 to 44)
Allergic contact der-
matit is
Study populat ion RR 3.94
(0.46 to 34)
3012
(3 RCTs)
⊕©©©
VERY LOW 2,3
Downgraded for risk of
bias (-2)
Downgraded for Impre-
cision (-1)
There were 5 (out of 1255) cases of allergic con-
tact dermatit is with topical ant ibiot ics compared
with none (out of 1787) in the control groups
Anaphylaxis Not reported N/ A N/ A
Patterns of ant ibiot ic
resistance
Not reported N/ A N/ A
Wounds healed 5-14
days
Study populat ion
827 per 1000 827 per 1000
(794 to 854)
RR 1.00
(0.96 to 1.03)
1034
(2 RCT and 2 Q-RCTs)
⊕⊕©©
LOW 4
Downgraded for risk of
bias (-2)
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; OR: odds rat io; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 The proport ion of the information f rom studies at high risk of select ion bias is suf f icient to af fect the interpretat ion of the
results.
2 The conf idence interval was wide and crossed no ef fect (0.46 to 34)
3 The majority of information was f rom a study at high risk of select ion and performance bias, which also had unit of analysis
issues.
4 The majority of information was f rom studies at high risk of select ion, performance or detect ion bias.
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B A C K G R O U N D
Description of the condition
Many surgical procedures are conducted each year. The majority
of these procedures result in wounds that heal by primary inten-
tion, which means that the wound edges are brought together (ap-
proximated) using sutures, staples, clips or glue. Wounds can also
heal by secondary intention, then the edges are not approximated
and the wound heals by granulation, re-epithelialisation and con-
traction. Most wounds heal without complications but surgical
site infections (SSIs) can occur after surgery in the site where the
surgery took place. Most wound infections are caused by contam-
ination during surgery with the patient’s own micro-organisms
(Kulaylat 2007). Theymay be superficial and self-limiting, involv-
ing the skin only, or they may be deeper and life-threatening. SSIs
are classified by the Centers for Disease Control and Prevention
(CDC) as superficial incisional, deep incisional and organ/space
infections (CDC 2014; Mangram 1999).
SSIs account for up to 20% of all of healthcare-associated infec-
tions (Magill 2014). At least 5% of patients who have a surgi-
cal procedure will go on to develop an SSI, highlighting the im-
portance of good prevention, detection and management (NICE
2008). SSIs can delay healing, impair cosmetic outcomes and po-
tentially cause other morbidity, such as deeper infections, as well
as potentially increasing costs, and the consumption of healthcare
resources (Bratzler 2004).
In order to understand SSI, it is first important to understand
the classification of surgical wounds. Surgical wounds are tradi-
tionally classified into different categories, and infection rates vary
by category. This classification is important in order to predict
postoperative infection rates and thus aid the decision to prescribe
postoperative antibiotics, whether oral or topical (Table 1).
• Clean (class 1): Noninfective operative wounds in which no
inflammation is encountered, with no involvement of
respiratory, alimentary, genitourinary tract and oropharyngeal
cavity. Additionally, these wounds must be the result of elective
procedures, closed by primary intention and drained with closed
drainage system if required.
• Clean/contaminated (class 2): Operative wounds in which
either the respiratory, alimentary, or genitourinary tract is
entered under controlled conditions and with only minor
contamination. This category specifically includes wounds as a
result of operations involving the biliary tract, appendix, and
oropharynx, provided no evidence of infection or a major break
in sterile technique is encountered.
• Contaminated (class 3): Fresh, accidental wounds, resulting
from operations with major breaks in sterile technique or gross
spillage from the gastrointestinal tract, and incisions in which
acute, nonpurulent inflammation is encountered. This category
includes traumatic lacerations.
• Dirty (class 4): Old traumatic wounds with retained
devitalised tissue and those that involve existing clinical infection
or perforated viscera. Organisms causing postoperative infection
are likely to be present in the operative field before the operation.
In a general surgical setting the acceptable rate of infection fol-
lowing clean surgery (class 1) is less than 5% (Cruse 1980; Culver
1991; Mangram 1999). In contrast, clean contaminated wounds
(class 2) have a risk of infection of less than 10%. Therefore, in
a general surgical setting, oral antibiotic prophylaxis of surgical
wounds is usually considered optional for clean procedures, and re-
served for certain at-risk patients or high-risk procedures (Bratzler
2004). If guidelines for prophylaxis after general surgery are ex-
trapolated to a dermatological surgery setting, then most derma-
tological procedures, which are considered to be clean (class 1)
surgery, should not require prophylaxis, and most guidelines re-
flect this (Maragh 2005; Messingham 2005; Wright 2008). How-
ever, as in general surgery, even within cohorts with a low over-
all risk of infection, some procedures may be at higher risk and
infection rates may be greater than 5% in these high-risk groups.
Although limited guidelines exist for the use of oral antibiotics as
infection prophylaxis, there are no guidelines for the use of topical
antibiotics after general and dermatological surgery.
There is no universal agreement on the definition of SSI. A sys-
tematic review identified 41 different definitions, and 13 grad-
ing scales for SSI, the majority of which had not been validated
(Bruce 2001). The most widely accepted description for surgical
site infection, however, is based on the 1992 CDC classification,
in which infection must occur within 30 days of surgery and in-
volve skin or deep tissue at the incision site (Mangram 1999).
In addition, one of the following must apply:
• purulent discharge from the incisional wound;
• organisms are isolated on culture of aseptically obtained
wound fluid or tissue;
• one or more of the following is present: pain, tenderness,
localised swelling, redness, heat, or the surgeon has deliberately
re-opened wound (unless culture of the incision is negative);
• the treating doctor diagnoses a superficial incisional surgical
site infection. Stitch abscesses are not defined as infection.
Although this definition has limitations, it is the most widely im-
plemented standard definition of SSI, and is the closest to a gold
standard available. Even when using guidelines, the diagnosis is
still subjective and there may be inter- and intra-observer varia-
tion.
Description of the intervention
The most common method of application of topical antibiotics
is in the form of an ointment. Other possible delivery methods
include cream, lotion, solution, gel, tincture, foam, paste, pow-
der, and impregnated dressings. An ointment base classically con-
tains 80% oil and 20% water, and therefore is more occlusive
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and will drive the medication into the skin more rapidly than a
solution or cream base; thus ointments are an optimal delivery
method for topical antibiotics. The only data available on the fre-
quency of topical antibiotic use on wounds comes from a sur-
vey of plastic surgeons in the UK which revealed that 66% used
chloramphenicol eye ointment in their practice, mainly as pro-
phylaxis against infection (Erel 1999). Other uses for antibiotic
ointment include the treatment of secondarily infected wounds
(Leyden 1987), otitis externa, treatment of secondarily infected
eczema and the treatment of impetigo (AEG 2010). Antibiotic
ointments may also have a role in accelerating wound healing in
both acute and chronic situations (Berger 2000; Eaglstein 1980;
Geronemus 1979). Adverse effects may include allergic contact
dermatitis (Blondeel 1978; Leyden 1979; Marks 1998), anaphy-
laxis (Saryan 1998), and the theoretical possibility of antibiotic
resistance (Bradley 1995; Fukuda 2002; Miller 1996).
There are several different types of antibiotic ointments used in
clinical practice, and the preferred choice varies by country (Table
2). Many of these topical antibiotic agents contain antibiotics that
are not recommended for systemic use due to serious adverse ef-
fects. The risk of serious effects is considered low with topical use,
thus they are safe for use in this form (Kasten 1999).
How the intervention might work
The role of topical antibiotics is to reduce the microbial contam-
inant exposure following the surgical procedure. A surgeon may
choose to use a topical antibiotic on a wound after considering the
likelihood of infection and weighing up the risks and benefits of
treatment. There is a lack of evidence in the literature regarding
the effects of antibiotic ointment in preventing wound infection.
Topical antibiotics have a number of mechanisms of action. Chlo-
ramphenicol is a bacteriostatic broad-spectrum antibiotic that ex-
erts an effect by inhibiting protein synthesis of the bacteria and
interfering with transfer of activated amino acids to ribosomes.
Neomycin hasmoderate Gram-negative action through inhibition
of protein synthesis. Mupirocin is active against Gram-positive
aerobic bacteria by inhibiting bacterial protein synthesis (HCN
2014). Antibiotics differ from antiseptics as they target specific
organisms selectively, whereas antiseptics destroy or inhibit the
growth of organisms non selectively (McDonnell 1999).
Why it is important to do this review
Rationalising the use of antibiotics is important in order to reduce
the risk of antibiotic resistance. The evidence for use of topical an-
tibiotics is conflicting, and therefore a systematic review of trials is
important to guide clinical practice. In some countries, such as the
USA, topical antibiotics are available over-the-counter, whereas in
others they are only available when prescribed by a doctor. The ef-
fectiveness of this treatment is therefore important to consumers,
as well as health practitioners. Better information about effective-
ness could assist in rationalising use and contribute to controlling
development of antibiotic resistance in the community.
O B J E C T I V E S
The primary objective of this review was to determine whether
the application of topical antibiotics to surgical wounds that are
healing by primary intention reduces the incidence of SSI and
whether it increases the incidence of adverse outcomes (allergic
contact dermatitis, infections with patterns of antibiotic resistance
and anaphylaxis).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) and quasi-ran-
domized controlled trials (quasi-RCTs) with a parallel group de-
sign. Quasi-RCTs are trials which use a quasi-random allocation
strategy, such as alternate days, date of birth, or hospital number.
We included trials published as abstracts if sufficient data were
available. We also included unpublished RCTs if sufficient data
were available. We accepted trials with paired designs (one wound
treated with topical antibiotic, and the other treated without top-
ical antibiotic, at different sites in the same patient).
Types of participants
We included:
• people of any age, gender or country of origin who had
undergone surgical procedures where healing of the surgical
wound was planned by primary intention, i.e. where wounds had
edges approximated with sutures, staples, clips or glue;
• any surgical setting, including dermatology outpatients or
inpatients, emergency department, general surgery and primary
care;
• all types of surgery (i.e. by risk of contamination); and
• studies involving mixed populations (if the data allowed the
results from the relevant population to be extracted). Our
definition of mixed populations for the purpose of this review
was a trial in which some of the participants fulfilled the
inclusion criteria and others did not.
We excluded:
• studies involving people with wounds that were already
infected (secondarily infected wounds), i.e. we did not include
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antibiotics for treating - rather than preventing - wound
infection;
• wounds healing by secondary intention; and
• instances where there had been antibiotic irrigation or
washout of wounds, subcutaneous infiltration of the antibiotic,
or any topical treatment applied only prior to wound closure
(not after).
Types of interventions
The intervention was topical antibiotics in the form of ointments,
creams, lotions, solutions, gels, tinctures, foams, pastes, powders
and impregnated dressings. We excluded silver and antiseptics
from our definition of topical antibiotics. We required the top-
ical antibiotic to have been applied after the wound was closed
by primary intention, therefore we excluded antibiotic irrigation
and washouts, subcutaneous infiltration of antibiotics and any
topical treatment applied only prior to closure of the wound. We
also excluded studies of antibiotic-coated sutures. We originally
planned to exclude studies where patients received concomitant
systemic antibiotics, however these studies were included. We in-
cluded single application postoperatively, or multiple applications
in the postoperative period. We recorded dosage of antibiotic if
this information was available. The topical antibiotic may have
been applied with or without a dressing. The comparison group
was placebo - which could have contained the vehicle of the topical
antibiotic - oral antibiotic, alternative topical antibiotic, topical
antiseptic or no treatment. We did not consider the comparator
groups to be homogenous for the purposes of data synthesis.
Types of outcome measures
We did not consider outcomes to be eligibility criteria. We con-
sidered secondary outcomes with and without validated scales.
Primary outcomes
• SSI, as defined by the CDC definition of SSI. In this
definition infection must occur within 30 days of the procedure,
therefore this time point was used as a cut-off for this primary
outcome measure. We also accepted the trial authors’ definitions
of infection.
• Proportion of patients with any relevant adverse effect
within 30 days of the procedure, i.e. allergic contact dermatitis,
anaphylaxis, or infections with patterns of antibiotic resistance.
Secondary outcomes
• Wound healing: time-to-healing or proportion of wounds
healed at the end of the trial.
• Patient satisfaction measured within six months of the
procedure.
• Health-related quality of life at 30 days and three months.
• Financial cost for each infection prevented (number needed
to treat for an additional beneficial outcome (NNTB)). We
planned to make this calculation by using the NNTB to
calculate the financial cost of prescribing topical prophylactic
antibiotics to a number of patients in order to prevent a single
wound infection.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases to identify reports
of relevant RCTs or quasi-RCTs:
• Cochrane Wounds Specialised Register (searched 31 May
2016);
• The Cochrane Central Registrar of controlled trials
(CENTRAL; the Cochrane Library 2015, Issue 4);
• Ovid MEDLINE (1946 to 31 May 2016);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (searched 31 May 2016);
• Ovid Embase (1974 to 31 May 2016);
• EBSCO CINAHL (1982 to 31 May 2016).
The search was first conducted in May 2015. The search was
repeated in May 2016 to ensure currency of included studies.
The search strategies used forCENTRAL,OvidMEDLINE,Ovid
Embase and EBSCO CINAHL can be found in Appendix 1.
We combined the Ovid MEDLINE search with the Cochrane
Highly Sensitive Search Strategy for identifying randomized tri-
als in MEDLINE: sensitivity- and precision-maximising version
(2008 revision) (Lefebvre 2011).We combined the Embase search
with the Ovid Embase filter developed by the UK Cochrane Cen-
tre (Lefebvre 2011). We combined the CINAHL searches with
the trial filters developed by the Scottish Intercollegiate Guidelines
Network (SIGN 2015). We did not restrict studies with respect
to language, date of publication or study setting.
We searched the following clinical trials registries:
• ClinicalTrials.gov (www.clinicaltrials.gov);
• WHO International Clinical Trials Registry Platform
(ICTRP) (apps.who.int/trialsearch/Default.aspx);
• EU Clinical Trials Register (www.clinicaltrialsregister.eu).
Searching other resources
We searched the bibliographies of all retrieved and relevant pub-
lications identified by the database searches for additional eligible
trials. We contacted manufacturers and pharmaceutical compa-
nies regarding studies for inclusion.
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Data collection and analysis
We followed guidelines given by the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Deeks 2011), and Cochrane
Wounds.
Selection of studies
Two review authors (CHand JB) independently screened the stud-
ies identified by the literature search. These review authors an-
alyzed the titles and abstracts of all citations found through the
search strategy described above. They obtained a copy of the full
article for each citation reporting a potentially eligible trial. Inde-
pendently, the two review authors applied the eligibility criteria;
any discrepancies were resolved by consensus discussion with the
third review author (MVD). Where necessary and possible, addi-
tional information was sought from the principal investigator of
the trial concerned. We justified, in the final report, any exclu-
sion of a potentially eligible trial from the review. We completed a
PRISMA flowchart to summarize this process (Figure 1) (Liberati
2009).
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Figure 1. Study flow diagram
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Data extraction and management
Two review authors (CH and PL) independently extracted data.
We summarised data using a pre designed data extraction form.
We piloted the data extraction tool before use. Data from trials
published in duplicate were included only once. Any discrepancy
was resolved by discussion or in consultation with a third review
author (MVD).
We extracted the following data:
• source (study ID);
• eligibility (confirm eligibility for review);
• characteristics of the trial (date of study, setting, location of
care, country, source of funding);
• methods (study design, sequence generation, allocation
sequence concealment, blinding, other concerns about bias);
• participants (number, diagnostic criteria, age, sex,
comorbidities, class of wound);
• intervention (type of topical antibiotic, delivery vehicle,
dose, frequency of application, co interventions);
• comparative intervention (placebo ointment, alternative
antibiotic ointment, no treatment control);
• for each outcome of interest: outcome definition, unit of
measurement, upper and lower limits for scales;
• primary outcomes (definition of SSI, unit of measurement);
• secondary outcomes (outcome definition and unit of
measurement);
• results (number of participants allocated to each
intervention group, sample size, missing participants, summary
data - e.g. 2x2 data for dichotomous data, means and standard
deviations for continuous data, estimate of effect with confidence
intervals and P value, subgroup analysis).
• key conclusions of study authors.
Assessment of risk of bias in included studies
Two review authors (CH and PL) independently assessed each
included study. Assessment was undertaken using the Cochrane
tool for assessing risk of bias (Higgins 2011). The ’Risk of bias’
tool considers the domains of:
• sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• freedom from selective reporting; and
• other potential bias.
We acknowledge that there is no accepted definition of what con-
stitutes a trial at high risk of bias, therefore we set a threshold
so that trials that we assessed as being at risk for any one of the
following essential elements of risk of bias - sequence generation,
allocation concealment and assessor blinding - we considered to
be at high risk of bias. Also, if missing outcome data were un-
equally distributed over the intervention arms, we discussed this,
considered the study at high risk of attrition bias, and considered
performing intention-to-treat (ITT) analysis.
We completed a ’Risk of bias’ table for each eligible study. We
combined these data into a ’Risk of bias’ summary figure.
Measures of treatment effect
The primary outcome was dichotomous (SSI or no SSI) and was
measured using risk ratio as the effect measure, with 95% confi-
dence interval. We planned to use mean difference with standard
deviation and 95% confidence interval to analyse continuous vari-
ables (patient satisfaction) using the same scales. Where different
scales were used to assess continuous outcomes, we planned to use
standardised mean difference with standard deviation in the analy-
sis (Deeks 2011). Time-to-healing is a form of time-to-event data,
more correctly analyzed using survival methods which can account
for censoring (i.e. just for the time that people were observed, so
it takes account of when they dropped out); it would have been
inappropriate to report and analyse time-to-wound healing as if it
were a continuous variable unless everyone healed and there was
no loss to follow-up. In practice there were no continuous vari-
ables in our review, and time-to-event data were not available for
analysis in a usable format.
Unit of analysis issues
The unit of analysis in trials was most likely to be the patient
recruited into the trial. It was possible that cluster-randomized
trial designs would be encountered, for example randomisation
by surgeon, or by operating list, or by general practice surgery or
hospital. We planned to analyse such trials based on allocation,
using summary values for each cluster, allowing the clusters to
become the individuals and analyse them as such. We planned
to use analysis from the trials that adjusted for clustering. Where
trials did not adjust for clustering, we planned to attempt adjust
the analysis for correlation. This can be done through a number of
methods, ideally based on a direct estimate of the required effect
measure as stated in Deeks 2011. We planned to use the generic
inverse variance method in Review Manager 5 (RevMan 2014) to
pool data from cluster randomized trials (Deeks 2011). In practice,
there were no cluster-randomized trials encountered in our review.
If there were three arms in a study, where two of the arms were
clinically similar, for the purposes of the review, we combined
them to create a single pair-wise comparison. Where we could not
combine arms and we includedmultiple arms in the same analysis,
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we planned to divide the control group(s) between the two arms
for the purpose of comparison.
In order to avoid unit of analysis errorwhenmeasurement occurred
at multiple time points, we planned only to pool data from one
time point that was closest to that of the other included studies.
Including multiple wounds
We considered adjusting for clustering when multiple wounds
were included in the same patient. We could not find a published
standard value for the inter-cluster correlation (ICC) that should
be used to adjust for clustering for this scenario. Therefore we
explored three potential situations with different values used for
ICC, and then performed a sensitivity analysis on the overall effect
of the two most extreme scenarios on the overall results.
Dealing with missing data
If the results of a trial were published, but information on the
outcome of interest was not reported, we attempted, whenever
possible, to contact the trial authors for the missing information.
If continuous data were not presented as mean and standard devi-
ation, we planned, whenever possible, to contact the trial authors
to request the information in this format. If the data were not
available, we planned to impute the missing standard deviation by
borrowing from similar studies, or we calculated the standard de-
viation from P values, t values, confidence intervals or standard er-
rors, whichever was available. We followed the methods described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011). In the completed review, we report all efforts made
to obtain additional information.
Excluding participants from the analysis after randomisation, or
ignoring participants lost to follow-up can, in effect, undo the pro-
cess of randomisation, and thus potentially introduce bias into the
trial. Therefore, where possible, all analyses were to be by inten-
tion-to-treat (Hollis 1999). If participants were allocated to one in-
tervention (for example, antibiotic ointment), but after randomi-
sation underwent a different intervention (for example, placebo
ointment), they were to be analyzed according to their randomi-
sation allocation.
If the results for dichotomous variables were not reported in some
participants, we planned originally to base our analysis on both a
worst possible outcome (for example, wound infection occurred in
all non reported cases), and a best possible outcome (for example,
wound infection did not occur in any non reported cases). Where
participants were excluded from analysis without good cause we
planned to conduct a sensitivity analysis to determine any effect
of attrition bias.
Assessment of heterogeneity
We explored the presence or absence of heterogeneity using visual
inspection of forest plots. If there was no apparent face value het-
erogeneity (e.g. clearly different populations or types of wounds,
different category of control group) we performed a Chi2 test with
significance set at P value 0.10. We also calculated the I2 statistic
(Deeks 2011). This explores the proportion of variability caused
by heterogeneity rather than by chance. Thresholds for the inter-
pretation of the I2 statistic can be misleading. A rough guide to
interpretation of the I2 statistic is:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity; and
• 75% to 100%: represents considerable heterogeneity.
When interpreting and exploring the I2 statistic, we took factors
such as clinical and methodological heterogeneity - in particular
the placebo treatment used - along with whether the heterogeneity
was in the magnitude of effect or in the direction of effect, into
account, particularly where ranges overlapped (Deeks 2011). We
explored this further in subgroup analyses. We planned that if
heterogeneity was very high (> 75%), we would not pool these
studies; we explored the impact of heterogeneity on the overall
outcome with a sensitivity analysis (see Sensitivity analysis).
Assessment of reporting biases
We compared the reported outcomes with those stated in the pub-
lished protocol of the studies, if available, or in the methods sec-
tion of the published report, and also those listed in clinical tri-
als registries as both primary and secondary outcomes (for exam-
ple www.clinicaltrials.gov). If sufficient studies were identified (a
minimum of 10), we planned to assess the risk of publication bias
by creating a funnel plot using software within Review Manager
5 (RevMan 2014), using visual inspection and statistical tests for
asymmetry.
Data synthesis
One review author (CH) entered quantitative data into Review
Manager 5 (RevMan 2014), and a second (PL) checked the data.
We calculated summary estimates of treatment effect (with 95%
confidence interval) for each outcome and every comparison. For
continuous outcomes, we presented the pooled mean difference
with the standard deviation as ameasure of the spread. For dichoto-
mous outcomes, we calculated the risk ratio as the effect measure,
with 95% confidence interval. We also calculated the absolute risk
difference, that would allow us to calculate the NNTB. We meta-
analysed the results of clinically homogenous studies using Review
Manager 5 (RevMan 2014). We conducted meta-analyses using a
random-effects model. If insufficient data were available for meta-
analyses, we presented a narrative synthesis of the outcome across
the included studies. We presented all results in ’Summary of find-
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ings’ tables, and rated the quality of evidence using the GRADE
system (see below) (Schünemann 2011a).
’Summary of findings’ tables
We presented the main results of the review in ’Summary of find-
ings’ tables. These tables present key information concerning the
quality of the evidence, the magnitude of the effects of the inter-
ventions examined, and the sum of the available data for the main
outcomes (Schünemann 2011a). The ’Summary of findings’ ta-
bles also include an overall grading of the evidence related to each
of the main outcomes using the GRADE (Grades of Recommen-
dation, Assessment, Development and Evaluation) approach. The
GRADE approach defines the quality of a body of evidence as the
extent to which one can be confident that an estimate of effect or
association is close to the true quantity of specific interest. The
quality of a body of evidence involves consideration of within-
trial risk of bias (methodological quality), directness of evidence,
heterogeneity, precision of effect estimates and risk of publication
bias (Schünemann 2011b).
We presented the following primary outcomes in the ‘Summary
of findings´ tables:
• superficial surgical site infection;
• adverse events;
• the proportion of wounds healed during the time period.
Subgroup analysis and investigation of heterogeneity
Where there were sufficient trials of adequate size and it was pos-
sible to conduct subgroup analyses, we planned to conduct sub-
group analyses for:
• clean versus clean/contaminated versus contaminated
wounds;
• dermatological versus general surgery;
• class of antibiotic used;
• single application versus multiple applications; and
• no treatment control versus placebo ointment control.
Sensitivity analysis
We performed a sensitivity analysis to assess the impact of hetero-
geneity on the overall estimate of effect by first pooling all studies,
and subsequently removing the outlying studies that seemed to
be contributing to the statistical heterogeneity.We also performed
sensitivity analysis to assess the impact of risk of bias on the overall
effect measure. We compared the outcomes of these analyses and
described the implications for the conclusion of the review. We
removed studies at high risk of bias in order to assess the effect of
this on the result.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies tables for full details of the studies identified. We
did not identify any studies which were about to start. We are
not aware of any relevant ongoing studies (we checked ISRCTN
register on 31st May 2016).
Results of the search
The results of our search are documented in a PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses) flow
chart (Figure 1)
The search identified 763 studies of potential relevance. After the
first screening 66 citations were considered potentially relevant.
Full text articles of these abstracts were obtained and screened by
two review authors independently against the inclusion criteria.
No ongoing trials were identified.We are awaiting a reply from the
study authors of one study in order to allocated it to a classification.
Included studies
A total of 10 RCTs and four quasi-RCTs with 6466 partici-
pants met the inclusion criteria. One manuscript reported two
trials which were conducted consecutively (Gough 1990a; Gough
1990b); this was treated as two separate trials for the purpose of
the review.
Five of the included trials were published since 2006 (Dixon 2006;
Heal 2009; Khalighi 2014; Neri 2008; Pradhan 2009); the earliest
study was published in 1967.
Two trials were conducted in Australia (Dixon 2006; Heal 2009),
seven in Europe (Caro 1967; Gilmore 1973a; Gough 1990a;
Gough 1990b; Iselin 1990; Kamath 2005; Neri 2008), four in the
USA (Dire 1995; Hood 2004; Khalighi 2014; Smack 1996), and
one in Asia (Pradhan 2009). One European trial was conducted
in France, and translation was required (Iselin 1990).
The types of surgical procedures were varied, and included skin
cancer surgery (three trials) (Dixon 2006; Heal 2009; Smack
1996); repair of lacerations and soft tissue injuries (three tri-
als) (Caro 1967; Dire 1995; Hood 2004); circumcision (two tri-
als) (Gough 1990a; Gough 1990b); caesarian section (one trial)
(Pradhan 2009); appendicectomy (one trial) (Gilmore 1973a); hip
replacement (one trial) (Kamath 2005); hand surgery (one trial)
(Iselin 1990); umbilical laparoscopic port (one trial) (Neri 2008);
and cardiac device implantation (one trial) (Khalighi 2014).
Six studies involved minor procedures which were all conducted
in an outpatient or emergency department setting (Caro 1967;
Dire 1995; Dixon 2006; Heal 2009; Hood 2004; Smack 1996).
Eight studies involved major surgery which were conducted in
theatre (Gilmore 1973a; Gough 1990a; Gough 1990b; Iselin
1990; Kamath 2005; Khalighi 2014; Neri 2008; Pradhan 2009).
The surgical procedures in each trial were classified as being clean
(three trials) (Dixon 2006; Heal 2009; Smack 1996); clean con-
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taminated (seven trials) (Gilmore 1973a; Gough 1990a; Gough
1990b; Kamath 2005; Khalighi 2014; Neri 2008; Pradhan 2009);
contaminated (four trials) (Caro 1967; Dire 1995; Hood 2004;
Iselin 1990). There were no dirty procedures.
The type of topical antibiotic applied varied, and included
neomycin/bacitracin/polymixin B (four trials) (Caro 1967; Dire
1995; Gilmore 1973a; Hood 2004); chloramphenicol (two trials)
(Heal 2009; Kamath 2005); neomycin (one trial) (Khalighi 2014);
bacitracin (two trials) (Dire 1995; Smack 1996); rifamycin (two
trials) (Iselin 1990; Neri 2008); mupirocin (two trials) (Dixon
2006;Hood 2004); soframycin (two trials) (Gough 1990a;Gough
1990b); and fusidic acid (one trial) (Pradhan 2009).
The antibiotic formulations varied and included ointment (eight
trials) (Dire 1995; Dixon 2006; Heal 2009; Hood 2004; Kamath
2005; Khalighi 2014; Neri 2008; Smack 1996); cream (one trial)
(Pradhan 2009); spray (two trials) (Caro 1967; Gilmore 1973a);
impregnated dressing (two trials) (Gough 1990a; Gough 1990b);
and solution (one trial) (Iselin 1990). Two studies did not spec-
ify if the antibiotic was delivered as cream or an ointment (Iselin
1990; Pradhan 2009). The topical antibiotic was either compared
with no treatment control (six trials) (Caro 1967; Dixon 2006;
Gilmore 1973a; Kamath 2005; Khalighi 2014; Neri 2008); an al-
ternative topical antibiotic (two trials) (Dire 1995;Hood 2004); an
inert topical control (five trials) (Dire 1995; Dixon 2006; Gough
1990b; Heal 2009; Smack 1996); or an antiseptic (six trials) (Dire
1995; Gilmore 1973a; Gough 1990a; Iselin 1990; Khalighi 2014;
Pradhan 2009). One study compared one topical antibiotic with
another topical antibiotic (Hood 2004). None of the included
studies compared topical antibiotics with systemic antibiotics.
Four trials involved participants who were all given concurrent
systemic antibiotics in addition to the topical antibiotic or control
(Kamath 2005; Khalighi 2014; Neri 2008; Pradhan 2009), and
in one trial, only some of the participants were given systemic an-
tibiotics, but it was not specified which (Gilmore 1973a).
Seven studies used multiple applications of the study agent (Caro
1967; Gilmore 1973a; Hood 2004; Iselin 1990; Kamath 2005;
Neri 2008; Smack 1996). Three studies applied the study agent be-
fore and after suturing (Caro 1967, Gilmore 1973a; Iselin 1990),
and four studies usedmultiple applications of the study agent post-
operatively. One study applied the ointment three times per day
until the wound check appointment at approximately one week
(Hood 2004). Another study applied ointment at the time of su-
turing and at three days postoperatively (Kamath 2005), while
another applied ointment at the time of suturing and 12, 24, 36,
48 and 72 hours postoperatively (Neri 2008). A final study ap-
plied the study agent after suturing and then daily for four weeks
(Smack 1996).
There were two three-arm studies (Dixon 2006; Gilmore 1973a),
and two four-arm studies (Dire 1995; Khalighi 2014), included
in the review. One of the three-arm studies compared one topical
antibiotic, one antiseptic (povidone-iodine) and one no treatment
control (Gilmore 1973a). We compared the antibiotic arm with
the antiseptic arm in a single pair-wise comparison in one analysis,
andwith the no treatment arm in another analysis.The other three-
arm study compared one topical antibiotic, one paraffin ointment
and one no treatment arm (Dixon 2006). We combined the two
no antibiotic arms , and compared with the antibiotic arm in a
simple pair-wise comparison. One of the four-arm studies had two
antibiotic arms (bacitracin and neomycin/polymixin B/bacitracin
zinc), an antiseptic arm (silver), and an inert ointment control arm
(petroleum) (Dire 1995). We compared the combined two antibi-
otic arms with the antiseptic arm in one comparison, and with
the no antibiotic arm in another comparison. We compared the
bacitracin arm with the neomycin/polymixin B/bacitracin arm in
another analysis. In the other four-arm trial there was one topical
antibiotic group (neomycin) and three control groups (antiseptic
ointment, non-adherent dressing and standard dressing) (Khalighi
2014). We combined the antibiotic arm with the two combined
dressing arms in one comparison and the antiseptic arm in another
comparison. We were not required to divide the control group be-
tween the two arms for the purpose of comparison in any analysis.
One study identified in the most recent search (May 2016) is
awaiting classification (Ruiz 2015).
Primary outcome measures
Surgical site infection
Twelve of the trials reported SSI rates (Caro 1967; Dire 1995;
Dixon 2006;Gilmore 1973a;Heal 2009;Hood 2004; Iselin 1990;
Kamath 2005; Khalighi 2014; Neri 2008; Pradhan 2009; Smack
1996), although in one trial these data were not extractable for the
pooled data analysis for this outcome (Neri 2008). The definition
of infection varied, and six trials includedmore than one definition
of infection. One trial defined infection according to the CDC
criteria for SSI, (Heal 2009), which is considered to be the gold-
standard definition for wound infection (Mangram 1999). One
trial used another validated scale (SIGN 2015 ; Kamath 2005).
Seven trials used a self-devised set of clinical criteria (Dire 1995;
Gilmore 1973a; Hood 2004; Iselin 1990; Khalighi 2014; Neri
2008; Smack 1996), and six trials used a self-devised wound scale
to define infection (Dire 1995; Dixon 2006; Heal 2009; Hood
2004; Khalighi 2014; Smack 1996). Two trials required positive
wound swabs to define infection (Gilmore 1973a; Smack 1996). A
third trial included it as part of their definition of infection, but it
was not mandatory (Khalighi 2014). One trial did not record the
definition of infection used (Pradhan 2009), while another used
the term ’non-healing’ as its definition of wound infection (Caro
1967).
Adverse effects
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We specified in our protocol three adverse effects of interest as pri-
mary outcomes: allergic contact dermatitis, patterns of antibiotic
resistance and anaphylaxis.
Allergic contact dermatitis
Four trials measured allergic contact dermatitis as an outcome
(Dire 1995; Dixon 2006; Iselin 1990; Smack 1996), and two stud-
ies reported at least one event of allergic contact dermatitis (Dire
1995; Smack 1996). One trial reported ’cutaneous intolerance’
which was classified as allergic contact dermatitis for the purpose
of this review (Iselin 1990). One trial reported that there had been
no episodes of allergic contact dermatitis (Dixon 2006).
Patterns of antibiotic resistance
Four studies undertook wound swabs to assess patterns of an-
timicrobial resistance (Heal 2009; Kamath 2005; Khalighi 2014;
Smack 1996). Two studies reported infections with methicillin-
resistant Staphylococcus aureus (MRSA) (Kamath 2005; Khalighi
2014). The Kamath 2005 study reported two positive cultures
of MRSA in the control group while Khalighi 2014 reported
four positiveMRSA cultures and two positive methicillin-resistant
Staphylococcus epidermidis cultures, but did not report to which in-
tervention they belonged. Another trial reported a culture of S au-
reus which showed resistance to erythromycin (Heal 2009), and a
culture of Pseudomonas aeruginosa. Both of these swabs were taken
from participants in the control group. A final study reported nine
cultures of S aureus and one culture of Proteus mirabilis in the con-
trol group, and two cultures of P aeruginosa, one of an Enterobacter
species and one of P mirabilis in the intervention group (Smack
1996). There were no patterns of resistance in either group. Over-
all there were no patterns of antibiotic resistance in any of these
studies that was related to antibiotic use.
One study reported that pus culture from all infected wounds
showed Staphylococcus but did not specify how many participants
had a positive swab or if there were patterns of resistance (Pradhan
2009). One study stated that swabs of serous discharge were per-
formed, but provided no results (Gilmore 1973a). Another study
stated that wounds with abscess formation or involvement beyond
local site would be swabbed (Dixon 2006), but provided no re-
sults.
Anaphylaxis
No trials reported anaphylaxis.
Other adverse outcomes
Four studies measured or reported other adverse effects (Dixon
2006;Hood 2004; Iselin 1990; Khalighi 2014). In one study there
was a specified list of adverse events stated in the methods section
(adverse scar outcomes, postoperative bleeding, allergy to dress-
ing, allergy to skin preparation, postoperative pain, contact der-
matitis, local recurrence, subcutaneous fibrosis, granuloma, dehis-
cence, pruritus, persistent pain, nerve damage, ectropion, nodal
involvement and distant metastases) (Dixon 2006), however, from
this list, only scar complicationswere reported in the results as hav-
ing occurred. One study listed ’any adverse event’ which occurred
during the study period in the methods section (Hood 2004), but
did not define these adverse events - this study reported an episode
of paraesthesia around the wound site. One study measured and
reported further surgery as an adverse outcome (Iselin 1990). One
other study reported an episode of ’pocket infection’ which re-
quired removal of a pacemaker device and prolonged systemic an-
tibiotics which occurred in a control group (Khalighi 2014).
Secondary outcome measures
Wound healing
Six trials reported healing (Caro 1967; Gough 1990a; Gough
1990b; Iselin 1990; Neri 2008; Smack 1996). Three of the 14
included trials had extractable data for the outcome of wound
healing, and no data for SSI (Gough 1990a; Gough 1990b; Neri
2008). All of the six trials which reported wound healing reported
the proportion of wounds healed between five days and twoweeks,
rather than time to healing, or the proportion of wounds healed
at the end of the trial, and this time point differed significantly
between the studies. We changed the definition of healing in the
review, from proportion of wounds healed at the end of the trial or
time to healing, as stated in the protocol, to proportion of wounds
healed in 5 to 14 days.
Patient satisfaction
One trial reported patient satisfaction measured between six and
nine months of the procedure, which was not within the time
period of six months stated in our protocol (Dixon 2006).
Quality of life
No trials reported health-related quality of life at 30 days or three
months.
Financial cost per infection prevented
No trials reported the financial cost for each infection prevented
(NNTB). One study reported NNTB, but did not report a finan-
cial cost (Heal 2009). Another study planned to conduct a cost-
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effectiveness analysis comparing Bactroban to Neosporin antibi-
otic ointment (Hood 2004). As there was clear difference in effec-
tiveness of the two ointments in the trial, a basic comparison of
cost of each antibiotic was made.
Other outcomes
Although we did not pre specify pain as an outcome in our pro-
tocol, it was reported in five studies, (Dixon 2006; Hood 2004;
Iselin 1990; Kamath 2005; Neri 2008), and tenderness was re-
ported in two studies (Dire 1995; Smack 1996). In one study pain
was treated as a separate primary outcome (Neri 2008), while in
five it was included in the definition of SSI (Dire 1995; Dixon
2006; Iselin 1990; Kamath 2005; Smack 1996). In three studies
pain was classified as an adverse effect (Dixon 2006; Hood 2004;
Neri 2008), while in one study it was a component of patient sat-
isfaction scales (Dixon 2006).
Excluded studies
The Characteristics of excluded studies table provides details of
the trials that did not meet the inclusion criteria. In total, 52 stud-
ies were excluded after screening of the full text. There were a
number of reasons for the exclusions including two studies that
were not RCTs (Erel 1999, Thakur 1997); 15 studies that in-
cluded wounds healing by secondary intention (Andrew 2012;
Bayerl 2004; Blobel 1970; Bos 2007; Campbell 2005; Draelos
2011; Johnson 2005;Kircik 2013; Livingston 1990; Mann 2001;
Mayer 1973; Motta 2005; Ruschulte 2009; Taylor 2011; Wright
1980), and 26 studies where the antibiotic was applied only prior
to suturing (Andersen 1970; Andersen 1972; Bates 1974; Battista
2001; Bencini 1991; Bird 1971; Charalambous 2003; Czarnecki
1992; Evans 1974; Fielding 1965; Finch 1979; Gilmore 1973b;
Hildred 1977; Jackson 1971; Jensen 1975; Kenning 1980;Merrild
1985; Mountain 1970; Ostergaard 1981; Pollock 1975; Praveen
2009; Saik 1971; Tanphiphat 1976; Theophilus 2011; Vander
Salm 1989; Varga 2009). One study was excluded due to healing
by secondary intention and the surgery being on mucosal surfaces
(Nicholson 2004). A further two studies were excluded where the
intervention antibiotic was delivered systemically (Bluhm 1986;
Eason 2004), five where delivery was by irrigation (Juul 1985;
Olthuis 1968; Sarr 1988; Stoller 1965;Tanphiphat 1978), and one
study where the wound was already infected (Leyden 1985). Full
details are given in the Characteristics of excluded studies table.
Risk of bias in included studies
A summary of the assessment of risk of bias based on the criteria
outlined in Higgins 2011 is given in Figure 2 and Figure 3. Addi-
tionally a brief descriptive analysis of the studies is provided below.
One of the authors had a conflict of interest regarding assessment
of a study (Heal 2009), and an alternative author (MVD) rated
this study for risk of bias. In general, the overall methodological
quality of the included studies was relatively poor. We classified
studies as being at high risk of bias if they were rated as ’high
risk’ for any one of the three risk of bias criteria which we had
specified in the protocol. A total of seven studies were deemed to
be at high risk of bias (Caro 1967; Dixon 2006; Gilmore 1973a;
Gough 1990a; Gough 1990b; Iselin 1990; Neri 2008), five were
at unclear risk of bias (Dire 1995; Hood 2004; Kamath 2005;
Khalighi 2014; Pradhan 2009), and two at low risk of bias (Heal
2009; Smack 1996).
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Figure 2.
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Figure 3.
Three trials reported a sample size calculation (Dixon 2006; Heal
2009; Smack 1996). It was not clear whether informed consent
was obtained in seven trials (Caro 1967; Gilmore 1973a; Gough
1990a; Gough 1990b; Iselin 1990; Neri 2008; Pradhan 2009).
Ethics approval was reported in five studies (Dire 1995; Dixon
2006; Heal 2009; Hood 2004; Smack 1996).
Allocation
Sequence generation
Ten of the included studies were described as being ’randomized’.
Two provided information that confirmed that adequate sequence
generation had taken place (Heal 2009; Smack 1996), one study
selected discs from a barrel until empty and then repeated (Dixon
2006). One study used three coded lettering recurring seven times
every 21 cases (Gilmore 1973a). Four studies were quasi-random-
ized using alternate patients (Caro 1967; Gough 1990a; Gough
1990b; Iselin 1990), and in the remaining six studies the method
of random sequence generation was unclear.
Allocation concealment
In five trials it was unclear whether the randomisation sequence
was concealed at the point of participant contact (Dire 1995;Hood
2004; Khalighi 2014; Neri 2008; Pradhan 2009). In six of the
trials, the method of sequence generation meant that allocation
concealment was at high risk of bias (Caro 1967; Dixon 2006;
Gilmore 1973a; Gough 1990a; Gough 1990b; Iselin 1990). In
three studies, the method of allocation concealment was well de-
scribed and at low risk of bias (Heal 2009; Kamath 2005; Smack
1996).
Blinding
Blinding of participants and personnel
In four studies both the participants and personnel were reported
to be blinded (Dire 1995; Heal 2009; Hood 2004; Smack 1996),
and this could be verified in three studies (Heal 2009; Hood 2004;
Smack 1996). In three studies either just the participants (Gilmore
1973a), or just the personnel (Dixon 2006; Kamath 2005), were
blinded.
Blinding of outcome assessment
In five studies the outcome assessor was blinded to treatment al-
location (Gilmore 1973a; Heal 2009; Hood 2004; Kamath 2005;
Smack 1996), while in the remaining nine studies it was unclear
if the outcome assessor was blinded.
Blinding of participants, personnel and outcome assessor
Three trials blinded participants, personnel and outcome assessors,
(Heal 2009; Hood 2004; Smack 1996).
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Incomplete outcome data
Drop out rate described and acceptable?
There were no trials where participants were excluded from the
analysis in sufficient numbers to increase risk of bias. The drop out
rate was not greater than 20% in any trial, and numbers of drop-
outs were balanced between the intervention and control groups
when group allocation was recorded. In seven trials there were no
dropouts and all participants were analyzed (Dixon 2006; Gilmore
1973a; Gough 1990a; Gough 1990b; Khalighi 2014; Neri 2008;
Pradhan 2009). All of these studies were rated at low risk for attri-
tion bias. In one trial the number of dropouts was unclear (Caro
1967), and this study was rated unclear for attrition bias. In the
remaining six studies, the proportion of drop outs was recorded,
however in three of these it was not clear whether these were allo-
cated to the intervention or the control group (Dire 1995; Hood
2004; Kamath 2005). In another study, 39/465 (8.4%) partici-
pants who received the allocated treatment were lost to follow-
up, but the allocation group was unrecorded, so it was unclear
if this was balanced between the intervention and control groups
(Dire 1995). In one study 21/120 (17.5%) participants who re-
ceived their allocated treatment were lost to follow-up, but again
the allocation group was unrecorded (Hood 2004). One study re-
ported 8/100 (8%) participants were lost to follow-up because of
death or severe disability (Kamath 2005), but it was not specified
whether these participants were in the intervention or the control
group. In another trial 45/268 (16.7%) (20 control, 25 interven-
tion) participants who had received their allocated intervention
were lost to follow-up (Iselin 1990). One trial reported 28/912
(3%) (13 versus 15) participants who had received their allocated
intervention were lost to follow-up (Smack 1996). In this study
another 10 participants were randomized, but did not receive their
allocated intervention - it was not specified whether these partici-
pants were in the intervention or the control group. In one study
42/1014 (4.1%) (21 intervention, 21 control) randomized par-
ticipants were lost to follow-up (Heal 2009). We rated studies at
high risk of attrition bias if more than 10% of participants were
lost to follow-up and it was unclear if this was balanced between
intervention and control.
Intention-to-treat (ITT) analysis
Intention-to-treat (ITT) analysis involves the analysis of the re-
sults for all study participants according to the treatment groups
to which they were originally randomized, irrespective of what
happened subsequently (Hollis 1999). There is no consensus re-
garding the optimal way of dealing with missing data in meta-
analysis. For the purposes of this review, we defined ITT analysis
as occurring when all randomized participants were reported or
analyzed in the group to which they were allocated for the out-
come measurement of SSI, irrespective of non-compliance and co
interventions. In studies of wound infection, the outcome of SSI
cannot be measured in participants lost to follow-up. Seven trials
with no missing outcome data conducted an ITT analysis (Dixon
2006; Gilmore 1973a; Gough 1990a; Gough 1990b; Khalighi
2014; Neri 2008; Pradhan 2009). One trial used an alternative
definition of ITT which included protocol violators in the analy-
sis, but not participants lost to follow-up (Heal 2009). In one trial
it was unclear if there were missing outcome data (Caro 1967). In
the remaining five trials, there were no outcomes recorded for the
missing participants, so imputation would be required for them
(Iselin 1990; Dire 1995; Hood 2004; Smack 1996;Kamath 2005
). In three of these studies it was also not specified to which group
the missing participants had been allocated, so data imputation
for the group allocation would be required (e.g. assuming that
dropouts had been evenly distributed between the intervention
and the control group) (Dire 1995; Hood 2004; Kamath 2005).
An SSI rate of between 1% and 10% is typical and this was re-
flected in the included trials. If a sensitivity analysis was conducted
on a best/worst case scenario basis, with the worst-case scenario
assuming all missing participants were treatment failures (i.e. had
developed an infection) then the rate of SSI would be falsely ele-
vated in the intervention group to a rate greater than an expected
baseline infection rate. This scenario would also be extremely un-
likely, and does not reflect clinical reality. If we calculate the ITT
analysis on the best-case scenario that missing participants did not
develop an SSI, we do not think it would affect our results as
the maximum missing data were 17.5%. An alternative approach
would be to impute data based on the event rate observed in the
control group, however as rates of missing data were less than 20%
we do not think this is necessary. In summary we decided to per-
form a complete case analysis for all trials in the review, and we
recognise this issue in the assessment of attrition bias in the ’Risk
of bias’ assessment and then in the GRADE assessment.
Unit of analysis issues
Including multiple wounds
We did not encounter any cluster-randomized controlled trials
which randomized by surgeon, operating list or hospital, despite
anticipating that wewould and describing howwewould deal with
these in our in our protocol. However we did need to consider
adjusting for clustering when multiple wounds were included.
All studies except two included one wound per patient.
One study included multiple wounds per patient; randomisation
was at the level of the patient and the unit of analysis was also the
patient rather than thewound (Smack 1996).Wedidnot adjust for
clustering in this study as this was considered to be an aggregation
issue (losing results by combining wounds) rather than a clustering
issue. Only 10% of patients had multiple wounds.
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Another study included multiple wounds per patient and ran-
domisation was at the level of the patient, but the unit of analysis
was the wound (Dixon 2006).
We could not find a published standard value for the inter-cluster
correlation (ICC) which should be used to adjust for clustering
for this scenario. Therefore we explored three potential situations
using different values for the ICC, and then performed a sensitivity
analysis on the effect of the two most extreme scenarios on the
overall results. If the ICC was 1.0 (assuming all results within a
cluster are identical), as opposed to 0 (no correlation of results
within a cluster), we found that the risk ratio (RR) changed from
0.59 (95% confidence interval (95% CI) 0.43 to 0.81) to 0.57
(95%CI 0.43 to 0.75). As a result of these calculations we decided
to perform no additional adjustment for clustering as it seemed to
have a negligible effect on overall results.
Selective reporting
We attempted to compare the outcomes reported in the results
sections of trial reports with those listed in published protocols
of the studies, in clinical trials registries as both primary and sec-
ondary outcomes, or in the methods section of the published re-
port. We were not able to find any separately published protocols,
therefore all studies were considered as being at unclear risk of
publication bias. One study was registered in a clinical trials reg-
istry (Heal 2009), and did not show selective reporting. None of
the other studies showed selective reporting when we compared
the outcomes listed in the methods section of the published paper
with the published results.
Other potential sources of bias
Publication bias
We did not have sufficient studies (> 10) for the primary outcome
measure of SSI to assess for publication bias in any of our com-
parator groups.
Financial support
Three trial groups reported that they had received financial sup-
port; in two cases from pharmaceutical companies. One study was
supplied with the intervention and control agents by the manu-
facturer, Alvex Limited (Gilmore 1973a). Another study was sup-
ported by a grant from PfizerConsumer Healthcare whomanufac-
tured one of the study ointments used in this trial (Hood 2004). A
third study received funding through the Chris Silagy scholarship
from the Royal Australia College of General Practitioners, and the
study was reported as being independent of this funding (Heal
2009). The remaining 12 trials did not report financial support.
Baseline comparability
Six trials reported data that confirmed baseline comparability for
patient and wound characteristics (Dire 1995; Dixon 2006; Hood
2004; Iselin 1990; Khalighi 2014; Smack 1996). In seven tri-
als, baseline comparison was not discussed (Caro 1967; Gilmore
1973a; Gough 1990a; Gough 1990b; Kamath 2005; Neri 2008;
Pradhan 2009), while in one trial it was reported that treatment
groups were not comparable at baseline and adjustments were
made in the analysis to compensate for this imbalance (Heal 2009).
Effects of interventions
See: Summary of findings for the main comparison Topical
antibiotics compared with no topical antibiotic.; Summary of
findings 2 Topical antibiotics compared with antiseptic
Comparison 1: topical antibiotic compared with no
topical antibiotic
Primary outcome 1: surgical site infection (SSI)
We pooled the results of eight trials (5427 participants) using
a random-effects model to compare the effects of topical an-
tibiotics with no topical antibiotics on SSI rates (all comparator
groups combined). The ’no topical antibiotic’ comparator group
included inert ointment (Dire 1995; Dixon 2006; Heal 2009;
Smack 1996) and no treatment (Caro 1967;Dixon 2006; Gilmore
1973a; Kamath 2005; Khalighi 2014). Three studies were at high
risk of bias, three were at unclear risk of bias and two were at low
risk of bias. There were fewer SSIs with topical antibiotics than
without (RR 0.61; 95% CI 0.42 to 0.87; Analysis 1.1). There was
an absolute risk difference of 20 fewer SSIs per 1000 patients (95%
CI 7 fewer to 31 fewer) and a NNTB with topical antibiotics to
avoid one additional SSI (NNT) of 50. There was moderate inter
study heterogeneity (I² = 44%).The quality of evidence for this
outcome was graded as moderate, downgraded once for the pro-
portion of the information from studies at high risk of selection
bias, as this was sufficient to affect the interpretation of the results.
A further study for this comparison did not provide usable data
for this outcome (Neri 2008).
We performed a sensitivity analysis to examine the effect of re-
moving the studies at high risk of bias on I2 and RR (Caro 1967;
Dixon 2006; Gilmore 1973a). The effect estimate was robust to
removal of high risk of bias studies (RR 0.49, 95% CI 0.35 to
0.67; 3026 participants; 5 studies; I2 = 0%).
Primary outcome 2a: allergic contact dermatitis
Three trials (3012 participants) examined the effect of topical an-
tibiotics on the rate of allergic contact dermatitis when compared
with no topical antibiotic (Analysis 1.2). One study was at high
risk of bias, one was unclear and one was at low risk of bias. One
20Topical antibiotics for preventing surgical site infection in wounds healing by primary intention (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of these trials did not report any events (Dixon 2006). We found
no clear difference between groups for risk of allergic contact der-
matitis (RR 3.94, 95% CI 0.46 to 34.00; 3012 participants; 3
studies; I2 = 0%; P = 0.5). The estimate was highly imprecise. The
quality of evidence for this outcome was assessed as being very low
(downgraded twice for the majority of information being from a
study at high risk of selection and performance bias, and unit of
analysis issues, once for imprecision).
Primary outcome 2b: anaphylaxis
No study reported anaphylaxis.
Primary outcome 2c: patterns of antibiotic resistance
No study reported patterns of antibiotic resistance.
Secondary outcome 1: wounds healed by 5 to 14 days
Four trials for this comparison reported the proportions of wounds
that were healed at a defined point in time, rather than time to
healing.Three studies were at a high risk of bias, the remaining
study was at a low risk of bias. The four studies (1034 participants)
were pooled (Analysis 1.3); the time point at which healing was
assessed varied between 5 and 14 days. There was no clear dif-
ference in wounds healed (RR 1.00, 95% CI 0.96 to 1.03; 1034
participants; 4 studies; I2 = 0%).The quality of evidence for this
outcome was rated as low (downgraded twice for the majority of
information being from studies at a high risk of selection, perfor-
mance or detection bias).
Secondary outcome 2: patient satisfaction measured within
six months of the procedure
No study reported patient satisfactionmeasuredwithin sixmonths
of the procedure.
Secondary outcome 3: health-related quality of life at 30
days and three months
No study reported health-related quality of life at 30 days or three
months.
Secondary outcome 4: financial cost for each infection
prevented
No study reported the financial cost for each infection prevented.
Comparison 2: topical antibiotic compared with
topical antiseptic
Primary outcome 1: SSI
We pooled five trials (1299 participants) that compared topical
antibiotics with antiseptics using a random-effects model to ex-
amine effects on risk of SSI (Analysis 2.1). There were fewer SSIs
in those treated with topical antibiotics than with antiseptics (RR
0.49, 95% CI 0.30 to 0.80). This difference reflected an absolute
difference in risk of 43 fewer cases of SSI per 1000 people treated
with topical antibiotics instead of antiseptics (95% CI 17 fewer to
59 fewer per 1000; NNTB of 24). There was minor inter study
heterogeneity ( I2 = 12%). The quality of evidence for this out-
come was rated as moderate and was downgraded once because
the proportion of the information from studies at high risk of se-
lection, performance and attrition bias was sufficient to affect the
interpretation of the results.
Two studies were at high risk of bias and three were at unclear risk
of bias. We performed a sensitivity analysis to examine the effect
of removing the studies at high risk of bias on I2 and RR (Gilmore
1973a; Iselin 1990). The overall effect was robust to removal of
the high risk of bias studies (RR 0.39, 95% CI 0.20 to 0.76; 908
participants; 3 studies) and heterogeneity was reduced (I² = 0%).
Primary outcome 2a: allergic contact dermatitis
Two trials (541 participants) compared the effects of topical an-
tibiotics and antiseptics on the rates of allergic contact dermatitis
(Analysis 2.2). Pooled analysis indicated no clear evidence of a
difference (RR 0.97, 95% CI 0.52 to 1.82; I2 = 0%, P = 0.92).
One of the two studies was at high risk of bias and the other was at
unclear risk of bias.The overall quality of the evidence was rated as
very low (downgraded twice for the majority of information being
from a study at high risk of selection, performance and attrition
bias, and once for imprecision).
Primary outcome 2b: anaphylaxis
No trials reported anaphylaxis.
Primary outcome 2c: patterns of antibiotic resistance
No study reported patterns of antibiotic resistance.
Secondary outcomes 1: wounds healed at 5 to 14 days
Both trials reported the proportions of wounds healed at a defined
point in time, rather than time to healing and these were pooled
(Analysis 2.3) (time points varied between 5 and 14 days). There
was no clear evidence of a difference in wound healing (RR 1.65,
95% CI 0.58 to 4.72; 327 participants; 2 studies; I2 = 88%). Both
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studies were at a high risk of bias.The quality of evidence for this
outcome was graded as very low; downgraded twice due to all
of the information being from studies at high risk of selection,
performance, detection or attrition bias, once for imprecision and
once for inconsistency.
Secondary outcome 2: patient satisfaction measured within
six months of the procedure
No study reported patient satisfactionmeasuredwithin sixmonths
of the procedure.
Secondary outcome 3: health related quality of life at 30
days and three months
No study reported health-related quality of life at 30 days or three
months.
Secondary outcome 4: financial cost for each infection
prevented
No study reported the financial cost for each infection prevented.
Comparison 3: topical antibiotics compared with
alternative topical antibiotic
Primary outcome 1: SSI
One study (99 participants) was a head-to-head comparison of
mupirocin and neomycin (Hood 2004). There was no clear ev-
idence of a difference between mupirocin and neomycin in risk
of SSI (RR 0.20; 95% CI 0.01 to 4.14; P= 0.3). The quality of
evidence for this outcome was rated as very low, downgraded twice
for this single trial being at a high risk of attrition bias, and once
for imprecision.
Another study was a four-arm trial; two arms of which were antibi-
otic arms (combination ointment (neomycin sulfate, bacitracin
zinc, and polymyxin B sulphate) versus bacitracin zinc) (Dire
1995). Comparison of the results for these two arms showed no
clear evidence of a difference in risk of SSI (RR 0.83; 95%CI 0.26
to 2.63; 219 participants, P= 0.75).
These two trials did not compare similar topical antibiotics and
so were not pooled. The quality of evidence of this outcome was
rated as very low, and was downgraded twice for risk of bias and
once for imprecision.
There was no information available for the outcomes of allergic
contact dermatitis, anaphylaxis and patterns of antibiotic resis-
tance, or the secondary outcome measures of wound healing, pa-
tient satisfaction, quality of life or financial cost for either study.
Comparison 4: topical antibiotics compared with oral
antibiotics
There were no trials that compared topical antibiotics with oral
antibiotics.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Topical ant ibiot ics compared with ant isept ic for wounds healing by primary intent ion
Patient or population: people presenting for surgery where healing of surgical wound planned to be by primary intention
Setting: primary or secondary care
Intervention: topical antibiotic
Comparison: antiseptic
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with control Risk with topical an-
tibiotic
Surgical site infect ion Study populat ion RR 0.49
(0.3 to 0.8)
1299
(4 RCTs, 1 Q-RCT)
⊕⊕⊕©
MODERATE 1
Downgraded for risk of
bias (-1)
84 per 1000 41 per 1000
(25 to 67)
Allergic contact der-
matit is
Study populat ion RR 0.97
(0.52 to 1.82)
541
(1 RCT, 1 Q-RCT)
⊕©©©
VERY LOW 2,3
Downgraded for risk of
bias (-2)
Imprecision (-1)77 per 1000 75 per 1000
(40 to 140)
Anaphylaxis Not reported
Patterns of ant ibiot ic
resistance
Not reported
Wounds healed 5-14
days
Study populat ion
574 per 1000 947 per 1000
(333 to 1000)
RR 1.65
(0.58 to 4.72)
327
(2 Q-RCT)
⊕©©©
VERY LOW 4,5,6
Downgraded for risk of
bias (-2)
Imprecision (-1)
Inconsistency (-2)7
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; OR: odds rat io; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1The proport ion of information f rom studies at high risk of select ion, performance and attrit ion bias is suf f icient to af fect the
interpretat ion of results.
2 The conf idence interval was wide and crossed no ef fect (0.52 to 1.82)
3 The majority of information was f rom studies at high risk of select ion, performance and attrit ion bias.
4 All of the information was f rom studies at high risk of select ion, performance, detect ion or attrit ion bias.
5 The conf idence intervals were broad and crossed no ef fect (0.58 to 4.72)
6 Heterogeneity 88%
7Downgraded maximum of three t imes to very low quality
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D I S C U S S I O N
Summary of main results
The primary aim of this systematic review was to summarize and
interpret all the existing evidence for the effects of topical antibi-
otics on rates of surgical site infection (SSI) in surgical wounds
healing by primary intention. Ten randomized controlled trials
(RCTs) and four quasi-randomised controlled trials met the eligi-
bility criteria for inclusion in the review.
Surgical site infection
Topical antibiotics applied to surgical wounds healing by primary
intention probably reduce the risk of SSI relative to no antibiotic
and relative to topical antiseptics (moderate quality evidence).
Adverse effects
We are unable to draw conclusions regarding the effects of topical
antibiotics on allergic contact dermatitis due to lack of statistical
power (small sample sizes). Any use of a topical antibiotic needs
to be tempered by consideration of side effects such as allergic
contact dermatitis. The evidence for this outcome, while critical
in the decision making for the use of topical antibiotics, was found
to be of low quality. There were no data regarding patterns of
antibiotic resistance or risk of anaphylaxis reported in any of the
studies identified.
Wound healing
There was no clear evidence of an effect of topical antibiotics or
antiseptics on wound healing, however this comparison is under-
powered and the evidence is of very low quality, so a difference
cannot be ruled out.
Patient satisfaction
No data could be extracted from the included studies for the out-
come of patient satisfaction, according to our definition.
Patient quality of life
No data could be extracted from the included studies for the out-
come of quality of life, according to our definition.
Financial cost
Financial cost was not reported in any of the studies.
Overall completeness and applicability of
evidence
The trials were all conducted in clinical practice and the evidence
is clinically applicable. The settings that were used varied, but
were across a range of general surgical and dermatological surgery
settings, and involved a range of wound classes.
We were unable to complete any of our planned subgroup analyses
because of lack of a sufficient number of studies.
Some studies had very low baseline rates of infection of around
2% (Dixon 2006; Khalighi 2014; Smack 1996), for all other trials
the baseline rates were 10% to 20%. In several of the studies (Heal
2009; Gilmore 1973a; Pradhan 2009), this baseline infection rate
was higher than is considered to be acceptable and than would be
expected in normal clinical practice (Cruse 1980), and this may
limit the applicability of the evidence. This clinical heterogene-
ity is worthy of additional attention. The mean absolute risk re-
duction was 4.3% when compared with antiseptics and 2% when
compared with no treatment, but this result was heterogenous in
both comparisons and was much lower in the individual studies
with low baseline infection rates. Two of the three studies with
low baseline infection rate were trials of patients with clean (class
1) wounds - the baseline results in these studies raises a question
about whether prophylaxis should be attempted in populations
with clean (class 1) wounds. The number needed to treat for an
additional beneficial outcome was 24 in the antiseptic comparison
group and 50 in the no treatment comparator group, but again
this is based on a mean absolute risk reduction result which was
heterogenous, and it would be much higher in situations where
the baseline infection rate is low.
The decision to use topical antibiotics is complex, and any ben-
efit must be weighed against adverse effects and healthcare costs,
and therefore there are limitations to applying the findings of this
review clinically.
Quality of the evidence
The quality of the individual studies varied. There was a tendency
for older studies to have higher risk of bias. Year as an indicator
of bias and quality has been reported in analysis of Cochrane
reviews (Kicinski 2015). The majority of studies were more than
10 years old and did not follow CONSORT reporting guidelines
(Schulz 2010). Most bias in individual studies, and thus most
effect on quality, came frommethods that were at high risk of bias
for random sequence generation and allocation concealment, and
also lack of blinding of the outcome assessor. Two of the studies
were at a high risk and six studies at an unclear risk of attrition
bias, as data from all participants was not included in the analysis
25Topical antibiotics for preventing surgical site infection in wounds healing by primary intention (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and intention-to-treat (ITT) analysis had not been performed.
Although we considered imputation methods and ITT analysis
for these studies, we decided to perform complete case analysis for
all studies. We then reflected this in our assessment of attrition
bias in these individual studies, and also in our overall GRADE
criteria.
Using theGRADE criteria, there were no outcomes where wewere
required to downgrade the quality of the overall evidence because
the removal of high-risk studies impacted the overall result. We
downgraded quality where there was moderate to severe hetero-
geneity, as defined in our protocol (inconsistency of results). We
defined imprecision where the confidence interval of the overall
effect of an outcome crossed the line of ’no effect’ (or 1), in addi-
tion to the confidence intervals crossing either 0.75 or 1.25. We
rated all included studies as being direct in their relevance to the
review question. There was not a sufficient number of studies to
enable us to assess for publication bias for any of the outcomes.
The quality of the evidence varied by outcome. The quality of
evidence, and therefore our confidence in the effect size of our first
primary outcome measure, SSI, was moderate in both comparator
groups. However the quality of evidence for our second primary
outcome, allergic contact dermatitis, was rated as very low, and
this diminished our confidence in the effect size for this outcome.
RCTs need to be adequately powered so that they are able to detect
treatment effects of a specified size, should these exist. As the
incidence of SSI is often low, an adequate number of participants
needs to be recruited to detect a clinically significant difference.
Only three of the trials included in this review had sample size
calculations, and several of the trials which had reported no effect
were likely to have been inadequately powered for the effect size
to have reached statistical significance. In one study the baseline
incidence of SSI was lower than expected when the sample size
was calculated, which resulted in the study being underpowered
(Dixon 2006). Therefore we feel that some of the studies had
reported topical antibiotics to be ineffective inappropriately, rather
than acknowledging the limitations of their sample size.
Potential biases in the review process
There is some potential for bias in the review process, however
strict attention was paid to Cochrane reviewmethods to avoid bias
where possible.
One of the review authors led a study which was included in the
review (Heal 2009). The data extraction and risk of bias were
completed and checked by review authors who had no connection
with the particular study.
Secondly, evenwith exhaustive searches, it is possible that we could
have missed trials. No published protocols were identified for any
of the included trials. Only one trial was registered in a clinical
trials registry so that the outcomes listed could be compared with
the reported results (Heal 2009).
We did not generate a funnel plot to investigate for publication
bias, because of the small number of studies involved. Therefore
our ability to assess risk of overall publication bias was limited
because of the small number of studies available and the fact that
not all studies assessed the same outcomes. We did not perform a
statistical test for publication bias, as these tests are only valid if
there aremore than 10 studies, as they are otherwise underpowered
todetectmuch and tend to lead to conclusions that are not justified
(Sterne 2000).
Finally, some studies did not provide datawhich could be extracted
for all outcomes for use in the meta-analysis. When possible we
reported these studies descriptively.
Agreements and disagreements with other
studies or reviews
We identified one relevant editorial (Grey 2009a), two literature
reviews (Diehr 2007; Rosengren 2010a), and three previous sys-
tematic reviews (Huiras 2012;McHugh 2011; Saco 2015), which,
in all but one case (Saco 2015), concluded that there is little ev-
idence for the effects of topical antibiotics to prevent SSI, par-
ticularly in dermatological surgery. Only one existing study used
meta-analysis of pooled data (Saco 2015), and this was limited to
only four studies.
A systematic review and meta-analysis of topical antibiotics ver-
sus petroleum/paraffin for prevention of SSI for dermatological
procedures (including wounds healing by primary or secondary
intention) favoured topical antibiotics, with a pooled odds ratio
from four studies of 0.71 (95% CI 0.42 to 0.1.19) (Saco 2015). A
literature review, Diehr 2007, focused on topical antibiotics and
wound healing and used commentary from three of the studies in
our review to conclude that there was Level A evidence that an-
tibiotic ointments reduce infection rates (Dire 1995; Hood 2004;
Smack 1996). A systematic review which, in contrast to our re-
view, included non-randomised studies and antibiotic implants
and washouts, concluded that topical antibiotics reduce SSI rates
in some surgical procedures, namely joint arthroplasty, cataract
surgery, breast augmentation and abdominal surgery in obese pa-
tients, although they also concluded that evidence for topical an-
tibiotics is lacking outside these indications (McHugh 2011). An-
other literature review with similar inclusion criteria concluded a
lack of evidence for the use of local antibiotics (Huiras 2012). An
evidence-based review of topical antibiotic prophylaxis for derma-
tological surgery concluded that topical antibacterial ointments
make no difference to healing or the incidence of SSIs (Rosengren
2010a). An editorial drew on three of the studies included in this
review - Dixon 2006, Heal 2009, and Smack 1996 - to conclude
that topical antibiotics do not prevent SSI in class 1/clean minor
surgical procedures where appropriate preoperative preparation
and aseptic technique have been applied (Grey 2009a). This latter
conclusion is consistent with two international guidelines (NICE
2008; SIGN 2015), which recommend that antibiotic prophy-
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laxis, not limited to topical antibiotics, is not required for clean
minor surgical procedures. NICE guidelines also state “do not
use topical antibiotics in wounds healing by primary intention to
reduce the risk of surgical site infection” (NICE 2008). Our re-
view has contributed additional evidence, though practice must
be guided by clinical judgement of risks and benefits.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Topical antibiotics probably prevent surgical site infection (SSI)
whether comparedwith antiseptic or tono topical antibiotic (mod-
erate quality evidence). Our review only identified studies involv-
ing clean (class1), clean contaminated (class 2), and contaminated
(class 3) surgery, and we cannot draw any conclusions regarding
dirty (class 4) surgery. In clean (class 1) surgery, where the baseline
infection rate is already low, and the absolute risk reduction in SSI
is probably smaller, the case for the use of topical antibiotics is
weaker. We are unable to draw conclusions regarding the effects
of topical antibiotics on adverse outcomes such as allergic con-
tact dermatitis due to lack of statistical power (small sample sizes;
very low-quality evidence). We are also unable to draw conclu-
sions regarding the impact of increasing topical antibiotic use on
antibiotic resistance. Any risk of adverse events is important when
evaluating the use of topical antibiotics, and there is insufficient
evidence in this review to inform this judgement.
Implications for research
There are only a few high quality randomized controlled trials on
this topic, and also a lack of studies which measured the adverse
outcomes of allergic contact dermatitis and patterns of antibiotic
resistance. Other outcomes which were not assessed by our in-
cluded studies in the time frames defined by our protocol included
patient satisfaction, quality of life and cost. Further research of
these outcomes would be of benefit to provide a holistic under-
standing of the role of topical antibiotics in SSI prophylaxis, as
well as establishing stronger evidence for the safety of topical an-
tibiotic use.
Quantifying the additive benefit of topical to systemic antibiotics is
as yet unaddressed, and there is a case for future research to evaluate
the effects of topical antibiotics alone versus systemic antibiotics
alone versus a combination of systemic and topical antibiotics in
preventing SSIs.
It would be of interest to conduct studies assessing the effect of top-
ical antibiotics infection prophylaxis in subgroups which result in
a higher risk of SSI. This could be high-risk patients (for instance
patients with diabetes or immunosuppression), body sites or types
of surgery. This would help to confirm if higher-risk wounds re-
ceive more benefit from topical antibiotics, and establish groups
where they may be of more benefit.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Caro 1967
Methods 2-arm prospective quasi-randomised trial. Contaminated (class 3) surgery
Participants The study aimed to enrol 500 consecutive participants with superficial lacerations who
presented at St James’ Hospital, Balham; results from 432 participants were reported and
it is not clear whether the further 68 participants were enrolled
Exclusion criteria: people currently receiving antibiotics or requiring deep haemostatic
sutures
Setting: emergency department in residential London
Interventions Intervention (n = 197): neomycin/polymyxin B/bacitracin aerosol was applied to the
surface of the wound before and after suturing. Strength probably 3.5 mg:400[iU]:5000
[iU] in 1g
Control (n = 235): no intervention
Outcomes Wound healing (dichotomous) was assessed at 5 days for lacerations of head/neck and
at 10 days for other sites
Notes An attempt was made to collect 500 cases but, in fact, 432 were recorded. It is not clear
whether the further 68 participants were enrolled or to which group they may have been
allocated
Woundhealing definition: unhealedwound evidenced by erythemaor purulent discharge
Concurrent illness: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Alternate cases were allotted to the
antibiotic and no antibiotic group.”
Allocation concealment (selection bias) High risk Comment: Allocation by alternate partici-
pants would allow prediction of the alloca-
tion sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Blinding of participants and
personnel is not described. It is likely they
were not blinded as both groups would
be aware if the antibiotic was or was not
sprayed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: It is not reported who con-
ducted the outcome assessment and
whether they were blinded
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Caro 1967 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “An attempt was made to collect
500 cases but, in fact, 432were finally com-
pletely documented.”
Comment: It is unclear if 68 participants
were not included or not recorded for un-
known reasons. Thus it is unclear if inten-
tion-to-treat analysis was performed
Selective reporting (reporting bias) Unclear risk Comment: All outcomes listed in themeth-
ods section of the study were reported in
the results. Study protocol was not avail-
able to identify any unreported outcomes
Other bias Low risk Comment: None was identified.
Dire 1995
Methods 4-arm double-blind, placebo-controlled RCT. Contaminated (class 3) surgery
Participants 465 participants with minor, uncomplicated soft-tissue wounds < 12 h old for suturing
were enrolled. 426 participants were analyzed, 28 participants were lost to follow-up,
and 11 participants were excluded after study commenced for protocol violations
Exclusion criteria: puncture wounds; immunocompromise/co-morbidities; underlying
fracture/neurovascular compromise; allergy to agent; pregnancy; use of antibiotics within
previous 7 days
Setting: emergency department of Army Community Hospital in Texas
Interventions Intervention 1 (n = 109): bacitracin zinc ointment 500 U/g applied 3 times/day until
return for suture removal
Intervention 2 (n = 110): neomycin sulfate, bacitracin zinc, polymyxin B sulphate com-
bination ointment (probably 3.5 mg/5000 U/400 U per gram) applied 3 times/day until
return for suture removal
Intervention 3 (n = 99): silversulfadiazine cream 1% applied 3 times/day until return for
suture removal
Control (n = 108): petrolatum ointment applied 3 times/day until return for suture
removal
Outcomes SSI (dichotomous); SSI (0-4 wound scale, 4 = most severe infection); adverse effects
(dichotomous). All outcomes assessed at time of suture removal (time differed for site of
wound and was not specified)
Notes 28 participants were lost to follow-up, 11 participants were excluded for protocol viola-
tions
Definition of infection 1: presence of clinical criteria for wound infection
Definition of infection 2: severity of infection by self-developed wound scale
Definition of adverse effect: cutaneous hypersensitivity reaction reported
Concurrent illness: none
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Dire 1995 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: not reported
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: participants blinded using pre-
filled, identical vials. Blinding of person-
nel was unclear, however the study was re-
ported as double-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: wounds were examined by one
of the study authors. It is not clear which
author assessed outcomes and if any author
may have been aware of allocation, however
the study ws reported as double-blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 39 participants were missing
from analysis, this accounted for 8%of par-
ticipants. 28 randomized participants were
lost to follow-up and were not included
in the analysis. 11 participants were ex-
cluded after randomisation for protocol vi-
olations. It is not clear to which groups the
missing participants belonged, and there-
forewhethermissing outcomedatawas bal-
anced across interventions. ITT analysis
was not performed
Selective reporting (reporting bias) Unclear risk Comment: although not listed in the
methods section, an episode of ‘cutaneous
hypersensitivity´ was reported in the re-
sults. Study protocol was not available to
identify any unreported outcomes
Other bias Low risk Comment: none were identified
Dixon 2006
Methods Blinded, 3-arm, RCT. Clean (class 1) surgery
Participants 778participants, 18 years andolderwhowere able to consent and complywith treatment,
with 1801 skin lesions requiring excision
Exclusion criteria: skin contamination before surgery; surgical site not amenable to a
moist, occlusive dressing; known allergy to the dressing or study agent. Partial-thickness
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Dixon 2006 (Continued)
skin graft donor sites were not included
Participants, not wounds, were randomized to receive the intervention, but results were
reported by wound
Setting: metropolitan skin cancer clinic Geelong, Australia
Interventions Intervention: (n = 262 participants; 562 wounds) mupirocin ointment 20 mg/g
Comparative intervention: (n = 269 participants; 729 wounds) paraffin ointment
Control: (n = 247 participants; 510 wounds) no ointment
Outcomes SSI rates (dichotomous, using clinical criteria); postoperative pain (self-devised 6-point
scale, higher = greater pain); adverse outcomes/complications (dichotomous), clinically
assessed until healingwas complete, sutures were removed, or if a complication developed
Notes Definition of SSI: presence of clinical criteria for wound infection
Definition of adverse effects 1: presence of clinical criteria for complications and adverse
outcomes. This included allergic contact dermatitis
Definition of adverse effects 2: postoperative pain on a 6-point scale
Concurrent illness: None reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using coloured discs in a barrel, quote:
“Patients (not wounds) were randomized
prospectively to one of 3 groups by an in-
dependent person drawing one of 150 discs
(50 for each group) from a barrel; upon
completing the barrel the process was re-
peated.”
Comment: this method of random se-
quence generation, although a little uncon-
ventional, is acceptable in principle
Allocation concealment (selection bias) High risk Comment: the randomisation was per-
formed by an ’independent person’ draw-
ing coloured discs from a barrel, but actual
allocation concealment was not described.
If the ’independent person’ was the practice
nurse, then this was not concealed from the
researcher who applied the treatment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Neither surgeon nor patient was
aware of the randomisation, although pa-
tients could not be completely blinded to
the application of an ointment by the nurs-
ing staff.”
The nurse (personnel) and participants
were aware whether they applied/received
37Topical antibiotics for preventing surgical site infection in wounds healing by primary intention (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dixon 2006 (Continued)
an ointment or not. It was unclear whether
the active component could be differen-
tiated by colour or smell from the paraf-
fin ointment, and no attempt was made to
see if the patients were blinded successfully
by asking them which group they thought
they were in
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: it is not clear who assessed
wound outcomes. Only the surgeon was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: complete outcomedatawere re-
ported for all participants for infection and
adverse effect outcomes. ITT analysis was
performed
Selective reporting (reporting bias) Unclear risk Comment: there were no incidences of al-
lergic contact dermatitis. Several of the ad-
verse event outcomes that were listed in the
methods section of the study were not re-
ported in the results, however it is likely that
this is because they did not occur. Study
protocol was not available to identify any
unreported outcome
Other bias Unclear risk Comment: wounds instead of participants
were the basis for the main analysis
Gilmore 1973a
Methods 3-arm, double-blinded RCT. Clean/contaminated (class 2) surgery
Participants 253 participants undergoing elective or emergency open appendicectomy, 1 participant
was excluded postoperatively for meeting exclusion criterion. We have assumed this was
prior to randomisation
Exclusion criteria: drain removal through a separate incision
Setting: a busy district general hospital in Reading, London
Interventions Intervention (n=84):Dispray - neomycin sulphate/bacitracin zinc/polymyxinB sulphate
powder in a pressurised aerosol (3.5 mg:500 U:5000 U/g) was applied for 8 seconds
from 25 cm away into the open wound following peritoneal closure and after closure of
wound
Comparative intervention (n = 84):Disdine - 5%povidone iodine in a pressurised aerosol
was applied for 8 seconds from 25 cm away into the open wound following peritoneal
closure and after closure of wound
Control (n = 84): no aerosol applied.
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Gilmore 1973a (Continued)
Outcomes SSI (dichotomous) was assessed on day 6 postoperatively.
Notes 1 participant was excluded postoperatively for meeting exclusion criterion
Defintion of SSI: any purulent discharge from the wound or serous discharge with a
positive wound culture in a 4-week period
Concurrent illness: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Random allocation of patients to
treatment was achieved using the three-let-
tered coding (L, N, Q) recurring 7 times in
each 21 cases.”
Comment: it is unclear how the sequence
was generated.
Allocation concealment (selection bias) High risk Comment: allocation concealment was
not reported, however the randomisation
methodmay have allowed prediction of the
allocation sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The code was kept outside the the-
atre, and the surgeon was only told which
code was applicable after the appendix was
removed and the peritoneum closed.”
Comment: the surgeon conducting the op-
eration was not blinded. The surgeon was
not the outcome assessor. The patient was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: outcomes were assessed by a
registrar from another team or an infection
control nurse who were not aware of allo-
cation. It is unlikely blinding was broken
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: outcome data were recorded for
all participants; 1 participant was excluded
after enrolment, we have assumed this was
prior to randomisation and receiving inter-
vention. Itwas not clear towhich group this
participant had been allocated. ITT analy-
sis was performed
Selective reporting (reporting bias) Unclear risk Comment: outcome data were presented
for all outcomes listed in methods section,
although no wound swab results were re-
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Gilmore 1973a (Continued)
ported. Study protocol was not available to
identify any unreported outcomes
Other bias Unclear risk Comment: materials were supplied by Al-
lvex Limited who manufactured the sprays
that were used
Gough 1990a
Methods 2-arm quasi-randomised trial. Clean/contaminated (class 2) surgery
Participants 108 boys with medical indications for circumcision including persistent painful micturi-
tion with phimosis, > 2 episodes of balanoposthitis, true phimosis after 10 years of age
and balanitis xerotica obliterans
Exclusion criterion: non-retracting prepuce under the age of 10 without symptoms
Setting: boys with medical indication for circumcision at a children’s hospital in Manch-
ester, UK
Interventions Intervention (n = 54): wrapping with soframycin-impregnated tulle gras folded into a
bandage and applied to wound after closure until it came away spontaneously
Comparative intervention (n = 54): 0.5 inch ribbon gauze soaked in tincture of benzoin
compound and applied to the wound after closure until it came away spontaneously
Outcomes Wound healing (0-3 scale, 3 = healed) assessed at 1 week
Notes The study was abandoned after 108 cases, as dressing was adversely affecting healing in
1 group
Definition of wound healing: self-devised 4-point clinical scale
Concurrent illness: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients were allocated to each
group alternatively from the start of the
study irrespective of age or reason for cir-
cumcision.”
Allocation concealment (selection bias) High risk Comment: allocation concealment was not
reported. Alternate allocation would allow
prediction of sequence
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: blinding of patient and person-
nel was not reported.
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Gough 1990a (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: blinding of outcomes assessor
was not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: outcome data were presented
for enrolled participants
Selective reporting (reporting bias) Unclear risk Comment: outcome data were presented
for all outcomes intended to be measured.
Study protocol was not available for iden-
tification of any unreported outcomes
Other bias Low risk Comment: none were identified.
Gough 1990b
Methods 2-arm quasi-randomised controlled trial. Clean/contaminated (class 2) surgery
Participants 210 boys with medical indications for circumcision including persistent painful micturi-
tion with phimosis, > 2 episodes of balanoposthitis, true phimosis after 10 years of age
and balanitis xerotica obliterans
Exclusion criterion: non-retracting prepuce under the age of 10 without symptoms
Setting: boys with medical indication for circumcision at a children’s hospital in Manch-
ester, UK
Interventions Intervention: sofretulle dressing tied in place with sutures after wound closure. Sutures
were released at 24 h to allow dressing to fall away spontaneously
Comparative intervention: paraffin tulle dressing tied in place with sutures after wound
closure. Sutures were released at 24 h to allow dressing to fall away spontaneously
Outcomes Wound healing (0-3 scale, 3 = healed) assessed at 1 week
Notes Definition of wound healing: self-devised 4-point clinical scale
Concurrent illness: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients were allocated alterna-
tively to paraffin tulle or sofratulle dressing.
”
Allocation concealment (selection bias) High risk Comment: allocation concealment was not
reported. Alternate allocation would allow
prediction of sequence
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Gough 1990b (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: blinding was not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: blinding of outcome assessor
was not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: outcome data were presented
for all participants.
Selective reporting (reporting bias) Unclear risk Comment: outcome data were presented
for all outcomes listed in methods section.
Study protocol was not available for iden-
tification of any unreported outcomes
Other bias Low risk Comment: none were identified.
Heal 2009
Methods 2-arm prospective, double blind RCT. Clean (class 1) surgery
Participants 1014 participants presenting for minor skin excisions were enrolled, 42 participants were
lost to follow-up and so 972 participants were analyzed
Exclusion criteria: people: taking oral antibiotics or where antibiotics were clinically
indicated; on immunosuppressive therapy; requiring excision of sebaceous cyst; with an
allergy to study agent; personal or family history of aplastic anaemia
Setting: minor skin excisions conducted in general practice in a regional centre, Mackay,
Australia
Interventions Intervention (n = 509): Chloromycetin ointment 1% applied once by sterile forceps
immediately after suturing
Control (n = 505): paraffin ointment applied once by sterile forceps immediately after
suturing
Outcomes SSI: incidence (dichotomous); SSI severity (self-devised 0-4 scale, 4 = most severe in-
fection); adverse effects (dichotomous); NNTB (mathematical equation) assessed at the
time of removal of sutures
Notes 42 participants were lost to follow-up.
Definition of SSI - incidence: presence of criteria from CDC National Nosocomial
Infection Surveillance System definition of SSI (Mangram 1999)
Definition of SSI - severity: self-developed 5-point clinical scale
Definition of adverse effect: antimicrobial resistance confirmed by wound culture
Definition of NNTB: The number of wounds treated for each infection prevented
Risk of bias
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Heal 2009 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “We used computer generated ran-
dom numbers and opaque sealed envelopes
to randomise patients.”
Allocation concealment (selection bias) Low risk Comment: allocation was concealed in
opaque sealed envelopes so the recruiting
nurses did not know the allocation of the
next patient to be included in the study (ad-
ditional information from authors)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Only the principal investigator
was aware of the identity of the coded oint-
ments.”
Comment: participants andpersonnel were
blinded to the identity of the ointment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: nurses assessing patient for SSI
at the time of removal of sutures were
blinded to the identity of the ointment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: outcomedatawere not reported
for all randomized participants. 1014 par-
ticipants were randomized and 972 were
analyzed. Missing participants accounted
for 4% of the enrolled population and this
was balanced in both arms with 21 partici-
pants missing from the intervention group
and 25 from the control group. An alter-
native definition for ITT was used by the
study and a sensitivity analysis was per-
formed to assess this effect
Selective reporting (reporting bias) Unclear risk Comment: outcome data were presented
for all outcomes intended to be measured.
Whenwe compared the reported outcomes
to those listed in the trial registry (IS-
RCTN73223053), there was no selective
reporting. There was no study protocol
Other bias Low risk Comment: none were identified.
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Hood 2004
Methods 2-arm RCT. Contaminated (class 3) surgery
Participants 120 participants who sustained uncomplicated soft tissue wounds within the previous
24 h were enrolled; 99 participants were analyzed; 21 participants were lost to follow-up
Exclusion criteria: puncture wound, underlying fracture, use of antibiotics within the
last 7 days, known allergy to the study agents, wounds closed with Dermabond, wounds
which required use of oral/parenteral antibiotics or wounds infected at the time of
presentation
Setting: participantswith uncomplicated soft tissuewounds in an emergency department,
Ohio
Interventions Intervention: Bactroban 2%was applied towound immediately after closure and 3 times/
day until return for wound check
Comparative intervention: Neosporin (neomycin/polymyxin B/bacitracin zinc) 3.5 mg/
10000 U/400 U/g was applied to wound immediately after closure and 3 times/day until
return for wound check
Outcomes Superficial SSI - incidence (dichotomous); superficial SSI - severity(1-4 scale, 4 = most
severe); adverse effects - pre and post operative pain (visual analogue scale, not described)
; adverse effects - incidence (dichotomous)
Notes 21 participants were lost to follow-up, group not specified.
Definition of SSI - incidence: presence of clinical criteria for wound infection
Definition of SSI - severity: self-developed 4-point scale
Definition of adverse effects - pre and postoperative pain: self-reported pain using visual
analogue scale
Definition of adverse effects - incidence: safety assessment for any adverse event associated
with medication use during study period
Concurrent illness: diabetes mellitus
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: reported as randomized, how-
ever method of random sequence genera-
tion not reported
Allocation concealment (selection bias) Unclear risk Comment: method of allocation conceal-
ment not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patient, treating physician
and study investigators were blinded to the
identity of the study medication”
Comment: the study ointment was dis-
pensed in identical containers. The study
was reported as blinded and it is unlikely
blinding was broken
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Hood 2004 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: treating physician, patient and
study investigators were blinded to identity
of medication
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 21 participants were lost to fol-
low-up and not included in analysis. This
accounted for 17.5% of the enrolled pop-
ulation. It was not specified why these pa-
tients were lost to follow-up or to which
group theywere allocated. ITT analysis was
not performed
Selective reporting (reporting bias) Unclear risk Comment: it was stated in themethods sec-
tion that a cost-effectiveness analysis was
planned, however this was abandoned as
there were no difference between interven-
tion and control arms. Otherwise all out-
comes listed in methods were reported in
results. Study protocol not available for
identification of any unreported outcomes
Other bias Unclear risk Comment: sponsored by Pfizer who man-
ufactured topical antibiotics
Iselin 1990
Methods 2-arm quasi-randomised controlled trial. Contaminated (class 3) surgery
Participants 268 consecutive patients presenting for urgent hand surgery were enrolled. 45 partici-
pants were excluded after randomisation; 5 were included by mistake, 33 were lost to
follow-up, 5 were excluded for protocol violation, 2 for unknown cause
Exclusion criteria: patients currently receiving immunosuppressants including steroids,
renal or hepatic disease, allergy to iodine or rifampicin, burns, cutaneous laceration only,
iodising radiation, current malnutrition
Setting: hospital inpatients and outpatients
Interventions Intervention: before closure wound was rinsed with rifamycin solution and after closure
wound was covered with soaked pad of rifamycin
Control: before closure wound was rinsed with povidone iodine dermal solution and
after closure wound was covered with soaked pad of povidone iodine dermal solution
Outcomes SSI (dichotomous); adverse effect (dichotomous); wound healing (dichotomous)
Notes 45 participants were excluded after randomisation; 5 were included by mistake, 33 were
lost to follow-up, 5 were excluded for protocol violation, 2 for unknown cause
Definition of SSI: presence of clinical criteria for wound infection
Definition of adverse effects: cutaneous intolerance, need for further surgery, unspecified
general complications
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Iselin 1990 (Continued)
Definition of wound healing - proportion of wounds healed: clinical criteria for healing
at 1 week and 2 weeks
Concurrent Illness: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Comment: this study was quasi random-
ized, alternate patients were randomized
into 2 parallel groups
Allocation concealment (selection bias) High risk Comment: allocation concealment was
not described, however alternate allocation
would allow prediction of allocation se-
quence
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: participants andpersonnel were
unable to be blinded, as the 2 interventions
were different in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: blinding of outcome assessor
was not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 45 participants were excluded
after randomisation, this accounts for 17%
of enrolled participants. 20 missing partic-
ipants were from the intervention group
and 25 were from the control group. 5 were
included by mistake, 33 were lost to fol-
low-up, 5 were excluded for protocol vio-
lation, 2 for unknown cause.The analysis
was made per protocol rather than ITT
Selective reporting (reporting bias) Unclear risk Comment: outcome data were presented
for all outcomes listed in methods. Study
protocol was not available to identify any
unreported outcomes
Patients excluded from the trial were well
recorded, as were patients who dropped out
of the trial
Other bias Low risk Comment: none were identified
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Kamath 2005
Methods 2-arm, blinded RCT. Clean/contaminated (class 2) surgery
Participants 100 participants with a fractured neck of femur enrolled. 1 participant was excluded
after randomisation due to confirmed metastatic disease and 7 participants died before
completion of the trial
Exclusion criteria: pathological fractures, undisplaced intracapsular neck of femur frac-
tures requiring internal fixation
Setting: orthopaedic hospital inpatients at a District General Hospital, UK
Interventions Intervention: Chloramphenicol 1% ointment applied immediately after wound closure
and on day 3
Control: no ointment applied.
Outcomes SSI (dichotomous); adverse effects (dichotomous); wound healing (dichotomous)
Notes 1 participant excluded for confirmed metastatic disease, 7 participants died before com-
pletion of trial
Definition of SSI: presence of Scottish Centre for Infection and Enrinomental Health
guidelines for SSI surveillance
Definition of adverse effects: not defined - participants who developed chest infections,
urinary tract infections and positive wound swab results were included
Definition of wound healing: number of wounds not healed at 30 days
Concurrent illness: rheumatoid arthritis, diabetes mellitus, systemic medical condition
unspecified, smoker
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: study was reported as random-
ized but method of random sequence gen-
eration was not reported
Allocation concealment (selection bias) Low risk Quote: “All the cases once included in the
study were randomized in an opaque sealed
envelope, which was opened at the end of
the surgical procedure.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “All observations were done by one
tissue viability nurse, who was blinded as
to the treatment group of patients.”
Comment: participants were likely aware
of allocation (ointment vs no ointment)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: outcome assessor was blinded;
participants were not. Outcomes measured
were unlikely to be affected by blinding
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Kamath 2005 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: data not reported for all en-
rolled participants; 7 died during study and
1 participant was excluded due to mor-
bidity. Outcome data were not recorded
in these 8 subjects, who constituted 8/100
(8%) of the participants, but their allocated
groups were not specified. ITT analysis was
not performed
Selective reporting (reporting bias) Unclear risk Comment: outcome data were presented
for all outcomes listed in methods. Study
protocol was not available for identification
of any unreported outcomes
Other bias Low risk Comment: none were identified.
Khalighi 2014
Methods 4-arm RCT. Clean/contaminated (class 2) surgery
Participants 1008 participants who underwent transvenous cardiac electronic implantable device
insertions
Exclusion criteria: none reported
Setting: hospital in Eason, Pennsylvania
Interventions Intervention 1: povidone iodine ointment 10%, single dose applied immediately after
closure
Intervention 2: neomycin ointment 3.5 mg/g, single dose applied immediately after
closure
Control 1: non-antibiotic, non-antiseptic placebo (see authors additional notes below)
Control 2: sterile non-adherent pad applied immediately after closure (see authors ad-
ditional notes below)
Outcomes Surgical site inflammation/infection 4-point grading system ( A-B = inflammation, C-
D = infection); incidences of wound abscess or erosion of pacing system was part of
grade D infection. Wounds with discharge were swabbed. Infection could occur up to
12 months after procedure
Notes Adverse effects: positive wound swab cultures
Concurrent illness: diabetes mellitus, chronic kidney disease, malignancy, steroids (not
specified), anticoagulation therapy (not specified)
Quotes from direct correspondence with author: ”In the ‘non-antibiotic, non-antiseptic
arm of the trial’, these patients actually did not have an inert ointment applied to their
wound, we used regular sterile gauze (4x4 gauze folded in half ) as the dressing. The
neomycin and iodine ointment arms received the same dressing,. The ‘sterile adherent
pad’ arm only used “Telfa” (sterile non adherent pad) available commercially in most/all
hospitals
“Patients classified as having grade 1 and grade 2 superficial inflammations (echemosis,
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Khalighi 2014 (Continued)
oozing) were not considered as infection, since they ruled out to have infections (no
discharge/no positive cultures/no ’ill looking’ erythema).”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: study described as randomized,
but method of random sequence genera-
tion was not reported
Allocation concealment (selection bias) Unclear risk Comment: not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: blinding was not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: outcome data were reported for
all participants. Analysis was per ITT
Selective reporting (reporting bias) Unclear risk Comment: outcome data were presented
for all outcomes listed in the methods sec-
tion. Study protocol was not available for
identification of any unreported outcomes
Other bias Low risk Comment: none were identified.
Neri 2008
Methods 2-arm, prospective RCT. Clean/contaminated (class 2) surgery
Participants 48 participants with uncomplicated gallstones undergoing video-laparoscopic cholecys-
tectomy during study period
Exclusion criteria: acute cholecystitis with localised peritonitis, umbilical hernia, im-
munodepressed patients, uncompensated diabetes, perforation of the gallbladder in the
peritoneal cavity during procedure, perforation of the gallbladder during its removal
through the umbilicus with bile leakage
Setting: uncomplicated laparoscopic cholecystectomy patients in a metropolitan Italian
surgical ward
Interventions Intervention: 3 mL rifamycin ointment (250 mg) applied to umbilical wound immedi-
ately after closure and at 12, 24, 36, 48 and 72 h postoperatively
Control: no ointment
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Neri 2008 (Continued)
Outcomes SSI - inflammation (dichotomous); SSI - purulent leakage (dichotomous); adverse effects
- postoperative pain (0-5 scale, 5 = worst pain); wound healing - dehiscence (dichoto-
mous); wounds healed at end of trial - incisional hernia (dichotomous)
Notes Definition of SSI - inflammation: presence of clinical criteria for infection
Definition of SSI - purulent leakage: presence of purulent leakage through umbilical
wound
Definition of adverse effects: postoperative pain at umbilical site rated by self-developed
6-point scale
Definition of wound healing: dehiscence: dehiscence of umbilical skin sutures during
study period
Definition of wound healing - incisional hernia: presence of incisional umbilical hernia
at 60 days postoperatively
Concurrent illness: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: reported as
randomized, method of random sequence
generation was unclear
Allocation concealment (selection bias) Unclear risk Comment: allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: it was likely participants would
be aware of allocation - administration of
ointment or no ointment. Blinding of per-
sonnel not reported
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: self-reported postop-
erative pain may be influenced by absence
of blinding. Measurement of other clini-
cal outcomes was unlikely to be affected by
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: outcome data were reported
for all participants, ITT analysis was per-
formed
Selective reporting (reporting bias) Unclear risk Comments: although it was stated that in-
fection would be measured, these data were
not extractable from the results section.
Study protocol was not available for iden-
tification of any unreported outcomes
Other bias Low risk Comment: none were identified.
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Pradhan 2009
Methods 2-arm RCT. Clean/contaminated (class 2) surgery
Participants 70 women undergoing emergency lower segment caesarean section, both primigravida
and multigravida were included
Exclusion criteria: not reported
Setting: emergency caesarean patients in a Nepalese hospital
Interventions Intervention: single dose of topical fusidic acid 2% was applied to wound immediately
after closure
Control: no ointment was applied after closure.
Outcomes SSI (dichotomous)
Notes Definition of SSI: presence of infection within 5 postoperative days. Criteria for infection
not reported
Concurrent illness: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: method of random sequence
generation not reported.
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: blinding of outcome assess-
ment was not reported. Measurement of
these outcomes was unlikely to be affected
by blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: outcome data were reported for
all participants. Analysis was per ITT
Selective reporting (reporting bias) Unclear risk Comment: outcome data were presented
for all outcomes listed in methods section
measured. Study protocol was not available
for identification of any unreported out-
comes
Other bias Low risk Comment: none were identified.
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Smack 1996
Methods 2-arm prospective, double-blind, RCT. Clean (class 1) surgery
Participants 922 participants with 1249 wounds who underwent dermatological surgical procedures
were enrolled in the trial, 884 participants with 1207 wounds were studied and analyzed
Exclusion criteria: pregnancy; age < 18 years; known allergy to bacitracin ointment; doc-
umented/suspected infection prior to procedure; documented HIV positivity; require-
ment of systemic antibiotic prophylaxis prior to surgical procedures
Setting: a general outpatient dermatology clinic and a tertiary referral advanced surgical
procedure clinic in Washington, DC
Interventions Intervention (n = 444 participants, 597 wounds): bacitracin ointment (500 U/g) applied
after procedure, daily for 7-10 days by participants and at follow-up appointments by
staff
Control (440 participants, 610 wounds): petrolatum ointment applied after procedure,
daily for 7-10 days by patients and at follow-up appointments by staff
Outcomes SSI - severity (0-2 scale, 2 = severe); SSI - confirmed infection (dichotomous); proportion
of adverse effects - allergy to ointment (dichotomous); wound healing (1-4 scale, 4 =
mature scar present)
Notes 38 participants with 42 wounds were lost to follow-up, 13 participants were allocated to
intervention group and 15 were allocated to control group. It is unclear to which group
the remaining 10 participants were allocated
Definition of SSI - severity: presence of pus, erythema, tenderness or itch - graded by
severity
Definition of SSI - confirmed infection: positive wound culture plus pus, erythema or
tenderness
Definition of adverse event: patch testing with bacitracin, neomycin and petrolatum for
participants who had a score of 2 for itch (see SSI - severity)
Definition of wound healing: clinical healing scale
Concurrent illness: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were assigned to a treat-
ment group using an ointment dispensing
list generated by a computer programbased
on random number generation.”
Allocation concealment (selection bias) Low risk Comment: each participant was random-
ized at pharmacy at time of collecting agent
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: personnel andparticipantswere
adequately blinded and it is unlikely this
blinding was broken
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Smack 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: outcome assessor was blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: enrolled participants were lost
to follow-up; 13 missing participants had
been allocated to the intervention group
and 15 to the control group. It was un-
clear to which group the remaining 10
missing participants were allocated. Miss-
ing participants accounted for 4% of the
enrolled population. ITT analysis was not
performed
Selective reporting (reporting bias) Unclear risk Comment: outcome data were presented in
results for all outcomes listed in methods.
Study protocol was not available for iden-
tification of any unreported outcomes
Other bias Low risk Comment: none were identified.
Abbreviations
ITT: intention to treat
NNTB: number needed to treat for an additional beneficial outcome
RCT: randomized controlled trial
SSI: surgical site infection
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andersen 1970 Pre-operative application of antibiotic, prior to closure.
Andersen 1972 Antibiotic applied prior to closure in this study.
Andrew 2012 Wound did not heal by primary intention.
Bates 1974 Antibiotic applied prior to closure in this study.
Battista 2001 Antibiotic applied prior to closure in this study.
Bayerl 2004 Wound did not heal by primary intention.
Bencini 1991 Antibiotic applied prior to closure in this study.
53Topical antibiotics for preventing surgical site infection in wounds healing by primary intention (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Bird 1971 Antibiotic applied prior to closure in this study.
Blobel 1970 Topical antibiotics to catheter to prevent UTIs, not applied to wound site after closure
Bluhm 1986 Study used systemic not topical antibiotics
Bos 2007 Wound did not heal by primary intention.
Campbell 2005 Wound did not heal by primary intention.
Charalambous 2003 Antibiotics applied prior to closure in this study.
Czarnecki 1992 Antibiotics applied prior to surgery in this study.
Draelos 2011 Wound did not heal by primary intention.
Eason 2004 Oral not topical antibiotics used in this study.
Evans 1974 Antibiotics applied prior to closure in this study.
Fielding 1965 Antibiotics applied prior to closure in this study.
Finch 1979 Antibiotics applied prior to closure in this study.
Gilmore 1973b Antibiotics applied prior to closure in this study.
Grandis 1994 Antibiotic not applied directly to wound in this study (parenteral antibiotic/antibiotic mouthwash used)
Hildred 1977 Antibiotics applied prior to closure in this study. Study was not randomised or pseudorandomised
Jackson 1971 Antibiotics applied prior to closure in this study.
Jensen 1975 Antibiotics applied prior to closure in this study.
Johnson 2005 Wound not sutured in this study. Not by primary intention.
Juul 1985 Study used antibiotic washout, not topical application after closure
Kenning 1980 Antibiotics applied prior to closure in this study.
Kircik 2013 Not by primary intention.
Leyden 1985 Wounds already infected in this study.
Livingston 1990 Wound did not heal by primary intention.
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(Continued)
Mann 2001 Wound did not heal by primary intention.
Mayer 1973 Topical antibiotics to catheter to prevent infection, not applied directly to sutured wound site after closure
Merrild 1985 Antibiotics applied prior to closure in this study.
Motta 2005 Wound did not heal by primary intention.
Mountain 1970 Antibiotics applied prior to closure in this study.
Nicholson 2004 Healing by secondary intention; mucosal surface.
Olthuis 1968 Study did not utilise topical antibiotic.
Ostergaard 1981 Antibiotics applied prior to closure in this study.
Pollock 1975 Antibiotics applied prior to closure in this study.
Praveen 2009 Antibiotics applied prior to closure in this study.
Ruschulte 2009 Wound did not heal by primary intention.
Saik 1971 Antibiotics applied prior to closure in this study. Pre-operative skin preparation used
Sarr 1988 Study used antibiotic washout, not topical application after closure
Stoller 1965 Study used antibiotic washout, not topical application after closure
Tanphiphat 1976 Antibiotics applied prior to closure in this study.
Tanphiphat 1978 Study used antibiotic irrigation, not topical application after closure
Taylor 2011 Wound did not heal by primary intention.
Thakur 1997 Journal club report of another clinical trial.
Theophilus 2011 Antibiotics applied prior to closure in this study.
Vander Salm 1989 Antibiotics applied prior to closure in this study.
Varga 2009 Antibiotics applied prior to closure (antibiotic impregnated sponge)
Wright 1980 Wound did not heal by primary intention.
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Characteristics of studies awaiting assessment [ordered by study ID]
Ruiz 2015
Methods RCT of topical mupirocin vs silver dressing vs no treatment
Participants Bowel surgery
Interventions Mupirocin, silver-impregnated dressing, no treatment
Outcomes SSI, antibiotic resistance
Notes Awaiting information from study authors
Abbreviations
RCT: randomized controlled trial
SSI: surgical site infection
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D A T A A N D A N A L Y S E S
Comparison 1. Topical antibiotic versus no topical antibiotic
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Surgical site infection 8 5427 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.42, 0.87]
2 Allergic contact dermatitis 3 3012 Risk Ratio (M-H, Random, 95% CI) 3.94 [0.46, 34.00]
3 Wounds healed in 5-14 days 4 1034 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.96, 1.03]
Comparison 2. Topical antibiotic versus antiseptic
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Surgical site infection 5 1299 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.30, 0.80]
2 Allergic contact dermatitis 2 541 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.52, 1.82]
3 Wounds healed in 5-14 days 2 327 Risk Ratio (M-H, Random, 95% CI) 1.65 [0.58, 4.72]
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Analysis 1.1. Comparison 1 Topical antibiotic versus no topical antibiotic, Outcome 1 Surgical site infection.
Review: Topical antibiotics for preventing surgical site infection in wounds healing by primary intention
Comparison: 1 Topical antibiotic versus no topical antibiotic
Outcome: 1 Surgical site infection
Study or subgroup Topical antibiotic No topical antibiotic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Caro 1967 18/197 27/235 17.6 % 0.80 [ 0.45, 1.40 ]
Dire 1995 (1) 11/219 19/108 14.2 % 0.29 [ 0.14, 0.58 ]
Dixon 2006 (2) 13/562 19/1239 14.4 % 1.51 [ 0.75, 3.03 ]
Gilmore 1973a (3) 8/84 15/84 12.2 % 0.53 [ 0.24, 1.19 ]
Heal 2009 32/488 53/484 21.9 % 0.60 [ 0.39, 0.91 ]
Kamath 2005 4/47 8/45 7.7 % 0.48 [ 0.15, 1.48 ]
Khalighi 2014 (4) 2/263 8/488 4.7 % 0.46 [ 0.10, 2.17 ]
Smack 1996 4/444 9/440 7.3 % 0.44 [ 0.14, 1.42 ]
Total (95% CI) 2304 3123 100.0 % 0.61 [ 0.42, 0.87 ]
Total events: 92 (Topical antibiotic), 158 (No topical antibiotic)
Heterogeneity: Tau2 = 0.11; Chi2 = 12.43, df = 7 (P = 0.09); I2 =44%
Test for overall effect: Z = 2.72 (P = 0.0065)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotic Favours no antibiotic
(1) Three arms of four arm study used in this comparison. The two antibiotic arms are combined and compared with the inert vehicle control arm.
(2) Three arm study. There are two no treatment control arms. This comparison is mupirocin intervention group v combined petroleum and no ointment control group
(3) Three arm trial. Topical antbiotic v no treatment control arm
(4) Three arms of four arm study. Neomycin arm v non-adherent dressing arm and standard dressing arms combined
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Analysis 1.2. Comparison 1 Topical antibiotic versus no topical antibiotic, Outcome 2 Allergic contact
dermatitis.
Review: Topical antibiotics for preventing surgical site infection in wounds healing by primary intention
Comparison: 1 Topical antibiotic versus no topical antibiotic
Outcome: 2 Allergic contact dermatitis
Study or subgroup Topical antibiotic No topical antibiotic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dire 1995 (1) 1/219 0/108 45.5 % 1.49 [ 0.06, 36.19 ]
Dixon 2006 (2) 0/562 0/1239 Not estimable
Smack 1996 4/444 0/440 54.5 % 8.92 [ 0.48, 165.17 ]
Total (95% CI) 1225 1787 100.0 % 3.94 [ 0.46, 34.00 ]
Total events: 5 (Topical antibiotic), 0 (No topical antibiotic)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotic Favours no antibiotic
(1) Four arm trial. The two topical antibiotic arms have been grouped as the experimental group compared with paraffin arm
(2) 3 arm trial. Mupriocin intervention group compared with parrafin ointment and no treatment control arm
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Analysis 1.3. Comparison 1 Topical antibiotic versus no topical antibiotic, Outcome 3 Wounds healed in 5-
14 days.
Review: Topical antibiotics for preventing surgical site infection in wounds healing by primary intention
Comparison: 1 Topical antibiotic versus no topical antibiotic
Outcome: 3 Wounds healed in 5-14 days
Study or subgroup Topical antibiotic No topical antibiotic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Caro 1967 (1) 179/197 208/235 26.4 % 1.03 [ 0.96, 1.09 ]
Gough 1990b (2) 39/105 44/105 1.0 % 0.89 [ 0.63, 1.24 ]
Neri 2008 (3) 24/24 24/24 17.2 % 1.00 [ 0.92, 1.08 ]
Smack 1996 (4) 156/164 174/180 55.5 % 0.98 [ 0.94, 1.03 ]
Total (95% CI) 490 544 100.0 % 1.00 [ 0.96, 1.03 ]
Total events: 398 (Topical antibiotic), 450 (No topical antibiotic)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.65, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotic Favours no antibiotic
(1) Not healed was considered in the same group as infected for the purposes of this study
(2) raw moist areas or dry scab (grade 0 or 1 on author developed healing scale) was considered unhealed
(3) rates of umbilical wound dehiscence at 1 week
(4) microsoft paint was used to derive actual numbers from measurements made from graphical data
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Analysis 2.1. Comparison 2 Topical antibiotic versus antiseptic, Outcome 1 Surgical site infection.
Review: Topical antibiotics for preventing surgical site infection in wounds healing by primary intention
Comparison: 2 Topical antibiotic versus antiseptic
Outcome: 1 Surgical site infection
Study or subgroup Topical antibiotic Antiseptic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dire 1995 (1) 11/219 12/99 31.8 % 0.41 [ 0.19, 0.91 ]
Gilmore 1973a (2) 8/84 7/84 22.4 % 1.14 [ 0.43, 3.01 ]
Iselin 1990 8/114 20/109 32.2 % 0.38 [ 0.18, 0.83 ]
Khalighi 2014 (3) 2/263 4/257 8.1 % 0.49 [ 0.09, 2.64 ]
Pradhan 2009 1/35 6/35 5.5 % 0.17 [ 0.02, 1.31 ]
Total (95% CI) 715 584 100.0 % 0.49 [ 0.30, 0.80 ]
Total events: 30 (Topical antibiotic), 49 (Antiseptic)
Heterogeneity: Tau2 = 0.04; Chi2 = 4.56, df = 4 (P = 0.33); I2 =12%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotic Favours antiseptic
compares with the silver antiseptic arm
(1) Dire used two antibiotic arms (Bacitracin and neomycin) an antiseptic arm (silver) and an inert vehicle control arm (petroleum). This calculation combines the two
antibiotic arms and
(2) This comparison uses two arms of this three arm trial: topical antibiotic experimental versus antiseptic control
(3) This comparison uses two arms of this four arm study. Neomycin arm v povidone iodine ointment arm of study
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Analysis 2.2. Comparison 2 Topical antibiotic versus antiseptic, Outcome 2 Allergic contact dermatitis.
Review: Topical antibiotics for preventing surgical site infection in wounds healing by primary intention
Comparison: 2 Topical antibiotic versus antiseptic
Outcome: 2 Allergic contact dermatitis
Study or subgroup Topical antibiotic Antiseptic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dire 1995 (1) 1/219 0/99 3.9 % 1.36 [ 0.06, 33.18 ]
Iselin 1990 16/114 16/109 96.1 % 0.96 [ 0.50, 1.82 ]
Total (95% CI) 333 208 100.0 % 0.97 [ 0.52, 1.82 ]
Total events: 17 (Topical antibiotic), 16 (Antiseptic)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours antibiotic Favours antiseptic
compares with the silver antiseptic arm
(1) Dire used two antibiotic arms (Bacitracin and neomycin) an antiseptic arm (silver) and an inert vehicle control arm (petroleum). This calculation combines the two
antibiotic arms and
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Analysis 2.3. Comparison 2 Topical antibiotic versus antiseptic, Outcome 3 Wounds healed in 5-14 days.
Review: Topical antibiotics for preventing surgical site infection in wounds healing by primary intention
Comparison: 2 Topical antibiotic versus antiseptic
Outcome: 3 Wounds healed in 5-14 days
Study or subgroup Topical antibiotic Antiseptic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gough 1990a (1) 22/54 8/54 44.4 % 2.75 [ 1.34, 5.63 ]
Iselin 1990 (2) 96/111 85/108 55.6 % 1.10 [ 0.97, 1.24 ]
Total (95% CI) 165 162 100.0 % 1.65 [ 0.58, 4.72 ]
Total events: 118 (Topical antibiotic), 93 (Antiseptic)
Heterogeneity: Tau2 = 0.51; Chi2 = 8.45, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antiseptic Favours antibiotic
(1) raw moist areas or dry scab (grade 0 or 1 on author developed healing scale) was considered non-healed
(2) delayed or slowed healing at 1-2 weeks was interpreted as not healed
A D D I T I O N A L T A B L E S
Table 1. Wound classification
Preoperative classification Wound type Maximum expected postoper-
ative infection rate
Example of wound
Class 1/clean Non contaminated wound 5% Sterile minor skin excision
Class 2/clean contaminated Operative wound in respira-
tory, alimentary, or genitouri-
nary tract, or minor break in
aseptic technique
10% Biliary tract, appendix, vagina,
oropharynx
Class 3/contaminated Open, fresh, accidental wound,
acute nonpurulent in-
flammation, gross spillage from
gastrointestinal tract,or major
break in aseptic technique
20% to 30% Open cardiac massage, gross
spillage from gastrointestinal
tract
Class 4/dirty-infected Purulent
inflammation, gross contamina-
tion with foreign bodies, pen-
30% to 40% Old traumatic wound, abscess
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Table 1. Wound classification (Continued)
etrating trauma more than 4-h
old, devitalised tissue
None
Table 2. Topical antibiotics
Ointment Trade name, avail-
ability
Mode of activity Range of activity Main use Side effects/ad-
ditional considera-
tions
Mupirocin Bactroban Inhibitor of bacte-
rial protein synthe-
sis
Gram-pos-
itive organisms, es-
pecially Staphylococ-
cus aureus
Impetigo, elimina-
tion of S aureus from
anterior nares
Anaphylaxis
reported
Bacitracin Ingredient of triple
antibiotic ointment
Interferes with bac-
terial cell wall syn-
thesis
Gram-positive
organisms
Impetigo, furuncu-
losis, pyodermas
Cross-sensitisation
with neomycin
Polymixin B Available singly,
combined with bac-
itracin or in triple
antibiotic ointment
Disrupts bacterial
cell membrane and
increases cell perme-
ability
Gram-negative or-
ganisms, including
Pseudomonas aerugi-
nosa, En-
terbacter species and
Escherichia coli
Bacterial
conjunctivitis
Limited spectrumof
activity
Neomycin Available
alone, or as ingredi-
ent of triple antibi-
otic ointment
Interferes with bac-
terial cell wall syn-
thesis
Aerobic Gram-posi-
tive and Gram-neg-
ative bacilli
Prevention of infec-
tion in superficial
abrasions, cuts or
burns
Allergic contact der-
matitis
Polymixin B,
neomycin and bac-
itracin
Triple antibiotic
ointment
Combination of
mechanisms
Range ofGram-pos-
itive and Gram-neg-
ative organisms
Prevention of infec-
tion in superficial
abrasions, cuts or
burns
Allergic contact der-
matitis
Erythromycin Eryacne Inhibitor of bacte-
rial protein synthe-
sis
Gram-positive cocci Acne Low incidence of
sensitisation
Chloramphenicol Chlormycetin or
Chlorsig
Disrupts bacterial
cell membrane
Wide
range of Gram-pos-
itive and Gram-neg-
ative organisms
Bacterial
conjunctivitis
Aplastic anaemia
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A P P E N D I C E S
Appendix 1. Search strategies
The Cochrane Central Register of Controlled Trials (CENTRAL)
#1 MeSH descriptor: [Antibiotic Prophylaxis] this term only
#2 MeSH descriptor: [Anti-Bacterial Agents] explode all trees
#3 MeSH descriptor: [Ointments] this term only
#4 MeSH descriptor: [Skin Cream] this term only
#5 MeSH descriptor: [Administration, Topical] explode all trees
#6 #1 or #2
#7 #5 and #6
#8 (topical near/5 antibiotic*):ti,ab,kw
#9 (mupirocin or bactroban or bacitracin or “polymixin B” or neomycin or erythromycin or chloramphenicol or chlormycetin or
chlorsig or neosporin):ti,ab,kw
#10 (antibiotic* near/5 (foam* or tincture* or gel or gels or solution* or lotion* or cream*)):ti,ab,kw
#11 (antibiotic* near/5 (powder* or liquid* or drop* or spray* or paste* or ointment*)):ti,ab,kw
#12 ((antibiotic* or impregnat*) near/5 dressing*):ti,ab,kw
#13 #3 or #4 or #7 or #8 or #9 or #10 or #11 or #12
#14 MeSH descriptor: [Surgical Wound Infection] explode all trees
#15 MeSH descriptor: [Surgical Wound Dehiscence] this term only
#16 (surg* near/5 infect*):ti,ab,kw
#17 (surg* near/5 wound*):ti,ab,kw
#18 (surg* near/5 site*):ti,ab,kw
#19 (surg* near/5 incision*):ti,ab,kw
#20 (surg* near/5 dehisc*):ti,ab,kw
#21 (wound* near/5 dehisc*):ti,ab,kw
#22 (wound* near/5 infect*):ti,ab,kw
#23 (wound* near/5 disrupt*):ti,ab,kw
#24 wound next complication*:ti,ab,kw
#25 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24
#26 #13 and #25
Ovid MEDLINE
1 Antibiotic Prophylaxis/
2 exp Anti-Bacterial Agents/
3 Ointments/
4 Skin Cream/
5 exp Administration, Topical/
6 1 or 2
7 5 and 6
8 (topical adj5 antibiotic*).tw.
9 (mupirocin or bactroban or bacitracin or polymixin B or neomycin or erythromycin or chloramphenicol or chlormycetin or chlorsig
or neosporin).tw.
10 (antibiotic* adj5 (foam* or tincture* or gel or gels or solution* or lotion* or cream*)).tw.
11 (antibiotic* adj5 (powder* or liquid* or drop* or spray* or paste* or ointment*)).tw.
12 ((antibiotic* or impregnat*) adj5 dressing*).tw.
13 3 or 4 or 7 or 8 or 9 or 10 or 11 or 12
14 Surgical Wound Infection/
15 Surgical Wound Dehiscence/
16 (surg* adj5 infect*).tw.
17 (surg* adj5 wound*).tw.
18 (surg* adj5 site*).tw.
19 (surg* adj5 incision*).tw.
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20 (surg* adj5 dehisc*).tw.
21 (wound* adj5 dehisc*).tw.
22 (wound* adj5 infect*).tw.
23 (wound* adj5 disrupt*).tw.
24 wound complication*.tw.
25 or/14-24
26 13 and 25
27 randomized controlled trial.pt.
28 controlled clinical trial.pt.
29 randomi?ed.ab.
30 placebo.ab.
31 clinical trials as topic.sh.
32 randomly.ab.
33 trial.ti.
34 or/27-33
35 exp animals/ not humans.sh.
36 34 not 35
37 26 and 36
Ovid Embase
1 antibiotic prophylaxis/
2 exp antibiotic agent/
3 exp ointment/
4 skin cream/
5 exp topical drug administration/
6 1 or 2
7 5 and 6
8 (topical adj5 antibiotic*).tw.
9 (mupirocin or bactroban or bacitracin or polymixin B or neomycin or erythromycin or chloramphenicol or chlormycetin or chlorsig
or neosporin).tw.
10 (antibiotic* adj5 (foam* or tincture* or gel or gels or solution* or lotion* or cream*)).tw.
11 (antibiotic* adj5 (powder* or liquid* or drop* or spray* or paste* or ointment*)).tw.
12 ((antibiotic* or impregnat*) adj5 dressing*).tw.
13 3 or 4 or 7 or 8 or 9 or 10 or 11 or 12
14 surgical infection/
15 wound dehiscence/
16 (surg* adj5 infect*).tw.
17 (surg* adj5 wound*).tw.
18 (surg* adj5 site*).tw.
19 (surg* adj5 incision*).tw.
20 (surg* adj5 dehisc*).tw.
21 (wound* adj5 dehisc*).tw.
22 (wound* adj5 infect*).tw.
23 (wound* adj5 disrupt*).tw.
24 wound complication*.tw.
25 or/14-24
26 13 and 25
27 Randomized controlled trials/
28 Single-Blind Method/
29 Double-Blind Method/
30 Crossover Procedure/
31 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or assign$ or allocat$ or volunteer$).ti,ab.
32 (doubl$ adj blind$).ti,ab.
33 (singl$ adj blind$).ti,ab.
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34 or/27-33
35 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
36 human/ or human cell/
37 and/35-36
38 35 not 37
39 34 not 38
40 26 and 39
EBSCO CINAHL
S39 S26 AND S38
S38 S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37
S37 MH “Quantitative Studies”
S36 TI placebo* or AB placebo*
S35 MH “Placebos”
S34 TI random* allocat* or AB random* allocat*
S33 MH “Random Assignment”
S32 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S31 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S30 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S29 TI clinic* N1 trial* or AB clinic* N1 trial*
S28 PT Clinical trial
S27 MH “Clinical Trials+”
S26 S13 AND S25
S25 S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24
S24 TI wound N1 complication* OR AB wound N1 complication*
S23 TI wound* N5 disrupt* OR AB wound* N5 disrupt*
S22 TI wound* N5 infect* OR AB wound* N5 infect*
S21 TI wound* N5 dehisc* OR AB wound* N5 dehisc*
S20 TI surg* N5 dehisc* OR AB surg* N5 dehisc*
S19 TI surg* N5 incision* OR AB surg* N5 incision*
S18 TI surg* N5 site* OR AB surg* N5 site*
S17 TI surg* N5 wound* OR AB surg* N5 wound*
S16 TI surg* N5 infect* OR AB surg* N5 infect*
S15 (MH “Surgical Wound Dehiscence”)
S14 (MH “Surgical Wound Infection”)
S13 S3 OR S4 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12
S12 TI ( (antibiotic* or impregnat*) N5 dressing* ) OR AB ( (antibiotic* or impregnat*) N5 dressing* )
S11 TI ( antibiotic* N5 (powder* or liquid* or drop* or spray* or paste* or ointment*) ) OR AB ( antibiotic* N5 (powder* or liquid*
or drop* or spray* or paste* or ointment*) )
S10 TI ( antibiotic* N5 (foam* or tincture* or gel or gels or solution* or lotion* or cream*) ) OR AB ( antibiotic* N5 (foam* or
tincture* or gel or gels or solution* or lotion* or cream*) )
S9 TI ( mupirocin or bactroban or bacitracin or “polymixin B” or neomycin or erythromycin or chloramphenicol or chlormycetin or
chlorsig or neosporin )ORAB (mupirocin or bactrobanor bacitracin or “polymixinB” or neomycin or erythromycin or chloramphenicol
or chlormycetin or chlorsig or neosporin )
S8 TI topical N5 antibiotic* OR AB topical N5 antibiotic*
S7 S5 AND S6
S6 S1 OR S2
S5 (MH “Administration, Topical+”)
S4 (MH “Creams”) OR (MH “Powders”)
S3 (MH “Ointments”)
S2 (MH “Antibiotics+”)
S1 (MH “Antibiotic Prophylaxis”)
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Appendix 2. Risk of bias assessment criteria
Random sequence generation
1. Low risk of bias: the method used was either adequate (e.g. computer-generated random numbers, table of random numbers) or
unlikely to introduce confounding (coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.)
2. Uncertain risk of bias: there was insufficient information to assess whether the method used was likely to introduce confounding.
3. High risk of bias: the method used was likely to introduce confounding with a non-random component in the sequence
generation process. For example: sequence generated by odd or even date of birth; sequence generation based on date (or day) of
admission; sequence based on hospital or clinic record number.
Allocation concealment
1. Low risk of bias: the method used was unlikely to induce bias on the final observed effect. Participants and investigators
enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal
allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation); sequentially-numbered drug
containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
2. Uncertain risk of bias: there was insufficient information to assess whether the method used was likely to induce bias on the
estimate of effect. For example the method of concealment is not described or not described in sufficient detail to allow a definite
judgement, for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially
numbered, opaque and sealed.
3. High risk of bias: the method used was likely to induce selection bias on the final observed effect. Participants or investigators
enrolling participants could possibly foresee assignments such as allocation based on: using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or
nonopaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed
procedure.
Blinding of participants and personnel
1. Low risk of bias: blinding was performed adequately, or the outcome or outcome measurement was not likely to be influenced
by lack of blinding.
2. Uncertain risk of bias: there was insufficient information to assess whether the type of blinding used was likely to induce bias on
the estimate of outcome effect.
3. High risk of bias: no blinding or incomplete blinding, and the outcome or the outcome measurement was likely to be influenced
by lack of blinding.
Blinding of outcome assessors
1. Low risk of bias: blinding was performed adequately, or the outcome or outcome measurement was not likely to be influenced
by lack of blinding.
2. Uncertain risk of bias: there was insufficient information to assess whether the type of blinding used was likely to induce bias on
the estimate of effect.
3. High risk of bias: no blinding or incomplete blinding, and the outcome or the outcome measurement was likely to be influenced
by lack of blinding.
Incomplete outcome data (attrition bias)
1. Low risk of bias: either no missing data, or the underlying reasons for missing data were unlikely to make treatment effects
depart from plausible values, or proper methods were employed to handle missing data. Missing outcome data balanced in numbers
across intervention groups, with similar reasons for missing data across groups.The proportion of missing outcomes compared with
observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate.
2. Uncertain risk of bias: there was insufficient information to assess whether the missing data mechanism in combination with the
method used to handle missing data was likely to induce bias on the estimate of effect.
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3. High risk of bias: the crude estimate of effects would clearly be biased due to the underlying reasons for missing data, and the
methods used to handle missing data were unsatisfactory (e.g. complete case estimate).
Selective outcome reporting
1. Low risk of bias: the trial protocol was available and all of the trial’s prespecified outcomes that are of interest in the review have
been reported; or, if the trial protocol was not available, all the primary outcomes in this review were reported.
2. Uncertain risk of bias: there was insufficient information to assess whether the study was high or low risk of bias for selective
outcome reporting.
3. High risk of bias: not all of the trial’s prespecified primary outcomes were reported.
Other sources of potential bias
1. Low risk of bias: the study appears to be free of other sources of bias.
2. Uncertain risk of bias: there may be a risk of bias but there is insufficient information to assess whether an important risk of bias
exists, or whether the identified problem will introduce bias.
3. High risk of bias: has a potential source of bias due to the specific study design used, or has some other problem.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The role of the authors changed between the protocol and the review. Two authors (CH and JB) independently screened the studies
identified by the literature search and analyzed studies for inclusion. PL extracted the data and CH checked the data for accuracy.
In one study (Heal 2009), an author (CH) had a conflict of interest and MVD conducted the risk of bias assessment for this study
together with PL.
Some of the trials involve spraying the wound with topical antibiotics both before and after suturing. We had not anticipated this,
and our protocol excluded studies with antibiotics used before closure, but included studies with antibiotics applied after closure. We
decided to include studies where topical antibiotics were applied both before and after closure.
In our protocol, we had excluded cases where the patient was concurrently on a systemic antibiotic. In practice, in many studies involving
major surgery it is routine to use systemic antibiotics perioperatively, or both perioperatively and postoperatively. If we exclude these
studies, we basically exclude any major surgery. We decided therefore to include these studies.
The definition of healing was changed in the review, from proportion of wounds healed at the end of the trial in the protocol to
proportion of wounds healed by 5 to 14 days. This was because all studies reported their healing in this time frame rather than at the
end of the trial. No trials reported time to healing, so this was not reported as an outcome measure. This is described in the results
section of the review.
We did not perform intention to treat (ITT) analysis, and the justification for this is described in the methods section.
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